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Advances in combination antiretroviral therapy (ART) have led to prolonged survival 
among people infected with HIV, with clinical focus shifting from acute illnesses to chronic 
diseases, including malignancies.[1, 2] Effective ART commonly suppresses viral load levels to 
below the detection limit of assays used in clinical practice in the US, but not all patients on ART 
are able to achieve virologic suppression to undetectable levels. Detectable HIV RNA under 
1,000 copies/mL has been studied as a potential risk factor for increased drug resistance, 
subsequent virologic failure, and mortality;[3-13] however, viral load measurements in this range 
are of uncertain clinical significance. HIV patients with low viral load under 1,000 copies/mL 
may not be receiving optimal clinical management, and the potential adverse consequences of 
low, detectable HIV RNA, such as the development of cancer and chronic disease, remain 
unclear. The objective of this project was to examine the clinical significance of low-level 
detectable HIV RNA under 1,000 copies based on the relationship between a single viral load 
measurement collected six months after treatment initiation and mortality, and to assess cancer 
risk among treated HIV patients with low, detectable viral load.   
We found that HIV patients with a single low-level viral load measurement between 400 
to 999 copies/mL shortly after starting therapy experienced a markedly higher 10-year risk of 
death (20%) compared to those with viral loads under 20 copies/mL (13%). In fact, these 






(between 1,000 to 4 million copies/mL) that indicated overt treatment failure (23%). We also 
found that the risk of a first cancer diagnosis in the 10 years following therapy initiation was 
6.9% in our study sample, and did not vary by viral load after controlling for baseline 
characteristics. Our overall findings highlight the importance of rapid viral load suppression 
after therapy initiation, and indicate that HIV patients with incomplete viral suppression shortly 
after starting antiretroviral therapy may require closer clinical monitoring and intervention, 
such as intensification or change of therapy, in order to increase the prospect of successful 
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CHAPTER 1. BACKGROUND 
 
Combination antiretroviral therapy suppresses viral replication and 
improves survival. Of the 37 million people living with HIV globally, 15 million, or 40%, are 
currently receiving antiretroviral therapy.[14, 15] Untreated HIV infection leads to the 
development of progressive immunosuppression due to CD4+ T-lymphocyte depletion, resulting 
in AIDS events and premature death. ART interrupts viral replication, reducing viral load in 
infected individuals and the risk of HIV transmission, and treatment initiation is currently 
recommended by the World Health Organization and US Centers for Disease Control and 
Prevention for all people with HIV, regardless of CD4 count.  
Effective ART typically suppresses HIV RNA levels to below the detection limits of assays 
used in clinical practice for the majority of patients in the US, and has led to an overall decline of 
average HIV viral load levels in the US[16] as well as decreased incidence of AIDS-defining 
illnesses.[1] Increased access to effective ART regimens has also led to improved survival in 
people with HIV, and the life expectancy of treated patients in the United States and Canada has 
dramatically increased in the past 15 years, approaching that of the general population.[17] As a 
result, it is estimated that by 2020, over half of all people infected with HIV/AIDS in the US will 
be over the age of 50.[18]  
 
The burden of cancer is on the rise among HIV patients on treatment. In the 
US, there are 1.2 million people are living with HIV/AIDS, with an estimated 50,000 new 






HIV/AIDS continues to normalize in the US, the incidence of age-related conditions, such as 
cardiovascular disease, diabetes, and osteoporosis, will correspondingly increase.[1] Because age 
is a primary risk factor for many malignancies, including anal cancer, liver cancer, lung cancer, 
and Hodgkin lymphoma, cancer has also become an increasingly significant cause of morbidity 
and mortality among people living with HIV/AIDS who are receiving effective ART. Between 
1991 and 2005, the burden of AIDS-defining cancers declined among people living with AIDS, 
but the burden of all other cancers in people with AIDS increased threefold.[1] Accordingly, the 
clinical focus of long-term HIV/AIDS care in the US has shifted from the treatment of acute 
illnesses to the prevention of chronic diseases.[1, 2] 
Due to immunosuppression, coinfections with other viruses, and elevated prevalence of 
certain risk behaviors, the risk of developing some cancers is higher among people infected with 
HIV compared to the general population.[20, 21] Half of all cancer cases that occur in people living 
with HIV/AIDS are in excess of expected rates among people who are not infected with HIV.[22] 
According to a cohort study comparing HIV-positive to HIV-negative individuals, the incidence 
rate ratio for AIDS-defining cancers was 22.5 and for non-AIDS-defining cancers was 1.9 during 
the period between 2004 and 2007.[23] Another recent large cohort study indicated that the 
crude cumulative cancer incidence by age 75 among people with and without HIV was 1.5% and 
0.05% for anal cancer, 0.9% and 0.09% for Hodgkin lymphoma, 1.1% and 0.4% for liver cancer, 
and 3.4% and 2.8% for lung cancer, respectively.[24] 
 
The clinical implications of detectable HIV RNA under 1,000 copies/mL 
remain unknown. HIV viral load, along with CD4 T-cell count, serves as an indicator of 
treatment response. Ideally, HIV patients on ART are able to achieve and maintain viral loads 
that are below the detection limits of commercial assays used in clinical practice. Due to a 






regimen complexities, and medical and psychiatric comorbidities, not all HIV patients on ART 
are able to achieve maximal suppression of viral load to undetectable levels. Only 72% of 9,323 
patients from the Antiretroviral Therapy Cohort Collaboration had viral loads of 500 copies/mL 
or below six months after ART initiation.[25] However, the clinical significance of HIV RNA levels 
that are in the detectable range but still considered low (typically below 1,000 copies/mL) is 
unclear.  
 Previous studies on low, detectable HIV RNA. Low, detectable viral load has 
been previously studied as a potential risk factor for outcomes including increased drug 
resistance, subsequent virologic failure, non-Hodgkin lymphoma, and mortality.[3-13, 26] In 
general, these studies have indicated that low, detectable viremia is associated with adverse 
outcomes compared to undetectable viral load. People with HIV with persistent low-level 
viremia (for at least six months) between 50 and 999 copies/mL were found to be at higher risk 
for virologic failure (defined as >1,000 copies/mL) compared to those with viral load below 50 
copies/mL.[5] HIV patients with current, three-month, and six-month lagged viremia of 51–500 
copies/mL were found to have an elevated risk of developing non-Hodgkin lymphoma compared 
to those with viral load at or below 50 copies/mL.[26] Increasing levels of viral load (1–19, 20–
399, 400–1,000, etc.) were associated with higher odds of five-year all-cause mortality 
compared to undetectable viral load, though there was no association after adjusting for CD4 
count and other factors.[6] 
Low, detectable viral load and cancer. The impact of low, detectable HIV RNA on 
cancer risk is uncertain and has not been rigorously explored in a longitudinal cohort with 
consideration of time-varying measurements obtained in clinical practice. Because low HIV 
RNA may be associated with inflammation[6, 27], it is biologically plausible that low, detectable 
viral load has predictive value in assessing the long-term risk of developing various cancers, 






viral infections. Low, detectable viral load may have a direct oncogenic effect in the development 
of malignant tumors, or may act through a mechanism of increased chronic inflammation 
and/or immune dysfunction in tissues with ongoing low-level HIV replication. 
No clear definition of low, detectable viral load. Despite previous studies 
evaluating the effects of low, detectable viral load, its clinical significance remains unclear. 
Epidemiologic and clinical studies tend to set the upper bound of low viral load somewhere 
between 200 to 1,000 copies/mL[3-13, 26, 28-30], while laboratory studies generally define low-level 
viremia as viral loads that are below the detection limit of assays commonly used in clinical 
settings, which usually range from 20 to 400 copies/mL).[31-33] The latter studies often use 
ultrasensitive assays that can quantify viral loads down to single copies per milliliter. Because 
the objective of this project was to characterize low, detectable viral load in a way that was 
relevant to clinical practice, we focused on low-level viral loads that were below 1,000 
copies/mL but above the detection limit of commercial assays. 
The varying limits of detection of viral load assays currently used in clinical practice 
further complicate the issue of evaluating low, detectable viral load. Viral load measurements 
are subject to an assay’s limit of detection, and the limit of detection for viral load assays 
currently used in clinical settings in the US can range from 20 to 400 copies/mL. The goal of 
ART is to suppress viral load levels to below assay detection limits, but this can be somewhat 
arbitrary given assay variability, and it is not clear how to compare undetectable viral load 









CHAPTER 2. SPECIFIC AIMS 
 
Using longitudinal data from a nationwide cohort of HIV-infected adults engaged in 
clinical care at eight Center for AIDS Research (CFAR) sites from the CFAR Network of 
Integrated Clinical Systems (CNICS),[34] we pursued the following specific aims: 
 
Aim 1: Determine whether there is a threshold of detectable HIV viral load 
under 1,000 copies/mL associated with increased all-cause mortality. We estimated 
10-year hazard ratios to ascertain whether there was a threshold of detectable HIV RNA under 
1,000 copies/mL six months after ART initiation that was associated with elevated all-cause 
mortality. We hypothesized that there would be a threshold of viral load under 1,000 copies/mL 
that corresponded to increased 10-year all-cause mortality compared to viral load under 20 
copies/mL.  
 
Aim 2: Assess the impact of detectable HIV viral load under 1,000 
copies/mL on first cancer risk. We estimated 10-year risk of first cancer diagnosis among 
patients with detectable HIV RNA under 1,000 copies/mL six months after ART initiation. We 
sought to evaluate cancer risk among patients with: (a) viral load under 20 copies/mL; (b) viral 
load between 20 copies/mL and the threshold identified in Aim 1; (c) viral load between the 
threshold identified in Aim 1 and 999 copies/mL; and (d) viral load at or above 1,000 
copies/mL. In the event that no clear threshold were identified in Aim 1, we planned to use a 






US Department of Health and Human Services and the AIDS Clinical Trials Group.[35] We 
hypothesized that, among HIV patients with detectable viral load under 1,000 copies/mL six 
months after ART initiation, those with viral load above the threshold identified in Aim 1 (or 
200 copies/mL) would have an elevated 10-year risk of developing cancer compared to those 
with viral load under 20 copies/mL. 
 
As the number of HIV patients on effective ART continues to rise, patients experiencing 
detectable HIV RNA under 1,000 copies/mL will be observed more frequently in clinical 
settings. Therefore, it is important to understand the implications of low, detectable viral load, 
particularly in relation to mortality risk. Additionally, as advances in ART continue to extend 
lives, cancer will be of growing public health significance among people living with HIV/AIDS, 
both in the US and worldwide. This research has the potential to provide important evidence to 
inform focused cancer intervention and screening practices specifically for treated patients 










CHAPTER 3. METHODS 
 
3.A. Study design 
For this study, we analyzed data from a multisite observational cohort of HIV patients in 
the US. The CNICS repository maintains standardized demographic, laboratory, medication, 
diagnosis, health care utilization, and vital status data sourced from electronic medical records 
and other institutional data systems.[34] Given the increasing life expectancy of HIV patients on 
treatment and the fact that many cancers occur more frequently in older adults, using extant 
data on an established patient cohort with long-term follow-up at multiple study sites was 
practical, efficient, and cost effective compared to enrolling and collecting primary data on a 
new study population. In addition, because CNICS patients are not recruited outside of routine 
clinical care, the findings of this study are less subject to volunteer and non-response biases 
than many observational studies. 
 
3.B. Study population 
We used data from the Center for AIDS Research (CFAR) Network of Integrated Clinical 
Systems (CNICS), a multicenter clinical cohort of over 30,000 HIV patients in the United States 
(Figure 3.1).  CNICS maintains a clinical data repository from electronic medical record systems 
to support HIV research.[34] The CNICS cohort includes patients aged 18 years and older who 
initiated primary care in or after 1995 at one of eight CFAR sites: Case Western Reserve 
University; Fenway Community Health Center of Harvard University; Johns Hopkins 






University of California, San Francisco; University of North Carolina at Chapel Hill; and 
University of Washington. CNICS is a dynamic cohort, with approximately 1,400 new patients 
enrolling and 10% of patients leaving care annually.[34] 
 




All participants provided written informed consent to be included in the CNICS cohort, 
or contributed data with a waiver of written informed consent where approved by local 
institutional review boards. Upon entry into CNICS, demographic and historical information, 
including prior diagnoses and antiretroviral treatment, was collected. After enrollment, patient 
data were prospectively captured at clinic visits and included prescribed medications, laboratory 
test results, and conditions diagnosed by providers. CNICS participants were typically seen in 






The CNICS cohort was well-suited for this study as it is the largest clinical cohort of HIV 
patients in the United States; by using data from CNICS, we expected our study findings to be 
generalizable to treated HIV patients engaged in clinical care in the US. Furthermore, over 30% 
of the CNICS cohort comprised patients aged 50 years and above (Figure 3.2), ensuring 
sufficient representation of the population typically at high risk for developing malignancies.  
 
Figure 3.2. CNICS cohort age distribution. 
 
Source: http://www.uab.edu/cnics/data-core/cnics-data-elements  
 
For the study, we examined a subset of the CNICS cohort. The study population included 
treatment-naïve patients who enrolled in CNICS and initiated combination ART (defined as 
three or more ART drugs prescribed concurrently) under observation between 1 January 1998 






recorded viral load measurement six months (-30/+90 days) after ART initiation. For patients 
who had more than one viral load during the 120-day window, we used the measurement that 
was collected closest to six months after the date of ART initiation. Date of ART initiation was 
defined as the date of concurrent prescription of three or more ART drugs. The overall study 
period was from 1 July 1998 to 31 December 2014 (Figure 3.3). 
 
Figure 3.3. Study period (indicated by red arrow). 
 
 
We excluded patients who initiated monotherapy or dual therapy with no record of 
initiating combination ART, initiated monotherapy or dual therapy prior to initiating 
combination ART, or initiated ART over 90 days prior to CNICS entry. Patients with missing 
race/ethnicity information, no recorded CD4 count six months (-30/+90 days) after ART 
initiation, no pre-ART viral load measurement recorded between 60 days prior to CNICS entry 
and 14 days after ART initiation, or pre-ART viral load measurements that suggested 
unrecorded prior exposure to treatment (<1,000  copies/mL) were also excluded. 
There were 27,865 patients who entered the CNICS cohort between 1 January 1998 and 
31 December 2013 (Figure 3.4). After applying our eligibility criteria, there were 7,944 patients 








Figure 3.4. Study eligibility. 
 
 
3.C. Exposure, outcome, and covariate assessment 
For this study, we used extant data collected by CNICS. These data include demographic 
information, clinical diagnoses, laboratory test results, medications, healthcare utilization, vital 
status, patient-reported measures and outcomes, antiretroviral resistance mutations, geospatial 
data, genetic data, and biologic specimens. 
Data in CNICS are sourced from point-of-care electronic medical records and other 
institutional data systems at the eight study sites.[34] Demographic and historical medical 
information, including prior diagnoses and antiretroviral treatment, are collected on each 
patient upon enrollment into the CNICS cohort. Once enrolled, laboratory test results, 






encounters and entered into the electronic medical record by clinicians at CNICS sites. CNICS 
participants are typically seen in clinical care every three to four months.  
Data quality assessments are conducted at all sites prior to data transmission and at the 
time of submission to the CNICS Data Management Core. After integration into the repository, 
all data undergo extensive, centralized quality checks, and all data quality issues are reported to 
CNICS site data managers by the Data Management Core to investigate and correct. Data from 
each site are updated, reviewed, and integrated into the repository quarterly.  
This study was subject to biases inherent in observational studies. Importantly, there 
may be factors that impact our associations of interest that are not measured in CNICS. That 
said, the quality of available data in CNICS is high, with the majority of clinical data collected 
prospectively (the exception being historical data collected at the time of entry into the cohort) 
and all data undergo extensive, standardized quality assurance procedures.[34] 
 
3.C.1. Exposure: Viral load 
The exposure of interest was HIV RNA six months after ART initiation. Viral load 
measurements were determined by quantitative amplification assays and expressed as the 
number of HIV copies per milliliter of blood plasma (copies/mL). Viral load assays used in this 
study varied over time and by CNICS site; the lower limits of detection for the most commonly 
used assays were 20, 30, 40, 48, 50, 75, and 400 copies/mL. Viral load measurements six 
months after ART initiation ranged from 6 to over 4 million copies/mL. 
Viral load assays have varying lower limits of detection. In assay development, the limit 
of detection is dependent on the limit of blank, or the highest measurement likely to be observed 
with a stated probability for a blank, or negative, sample. The limit of blank is estimated by 
testing replicates of a blank sample and is calculated as the mean blank sample measurement 






Figure 3.5. Limits of detection and quantification. 
 
 
level.[36] The limit of detection is the lowest concentration in a sample that can be detected with 
a stated probability. The limit of detection is estimated by testing replicates of a low 
concentration sample and is calculated as the limit of blank plus the product of the standard 
deviation of the low concentration sample measurements and a confidence level.[36, 37] The limit 
of quantitation/quantification is equivalent to or greater than the limit of detection. The linear 
range of an assay is bounded by its lower and upper limits of quantification, and represents the 
region over which the assay provides a linear response with acceptable accuracy (Figure 3.5). 
For viral load assays used at the CNICS sites, including the Abbott RealTime HIV-1 
Assay, Roche Amplicor HIV-1 MonitorTM Test, and Roche COBAS® AmpliPrep/TaqMan® HIV-
1 Test, the limit of detection was equivalent to the lower bound of the assay’s linear range (i.e., 
lower limit of quantification). While labs may specify whether a viral load result that was too low 
to be quantified was below or above the detection limit, this level of information was not 
provided in the CNICS data. For this project, the limit of detection was considered equivalent to 






Figure 3.6. Limits of detection and quantification (CNICS data). 
 
 
3.C.2. Aim 1 outcome: All-cause mortality 
The outcome of interest for Aim 1 was time to death from any cause. All CNICS sites 
regularly query the National Death Index and state death certificate records to confirm recorded 
dates of deaths and capture unrecorded deaths among CNICS patients no longer in care. We 
used all-cause mortality as our endpoint because cause of death data were unavailable for 
approximately 35% of deaths recorded in CNICS.  
Because vital records are maintained on all patients enrolled in CNICS, including those 
not currently retained in care, we included deaths among patients no longer being seen in a 
CNICS clinic in the analyses. We ended the study period on 31 December 2014 to account for 
reporting delays, which can result in underestimated mortality, and to allow sufficient time for 







3.C.3. Aim 2 outcome: First cancer diagnosis 
The outcome of interest for Aim 2 was time to diagnosis of first cancer, excluding 
nonmelanoma skin cancer. All cancer cases diagnosed through 31 December 2014 and recorded 
at the CNICS sites were verified by medical record review. Malignancy data collected by CNICS 
included date of diagnosis, tumor site, diagnosis method (histopathology, clinical exam, 
radiography, or historical information), histology, stage, and grade. For the analysis, we 
aggregated all incident cancers into a summary variable.  
 
3.C.4. Covariates 
The following variables were included in the analyses as potential confounders: 
 Age, which was based on year of birth. For all patients, we imputed a birthdate of July 1 of 
the year of birth, as exact birthdates were not available to protect patient confidentiality.  
 Sex, which was based on sex at birth. Present sex was used when information about sex at 
birth was missing.  
 Race/ethnicity, which was coded as white non-Hispanic, black non-Hispanic, other non-
Hispanic, and Hispanic. Separate variables for race and ethnicity were combined to derive 
this variable. 
 Male-to-male sexual contact, which was an indicator of ever having had male-to-male 
sexual contact. 
 Injection drug use, which was an indicator of ever having injected drugs. 
 Smoking, which was an indicator of ever having smoked. 
 At-risk alcohol use, which was an indicator of ever having reported at-risk alcohol use. 
 Pre-ART viral load, which was viral load collected between 60 days prior to entry in the 
CNICS cohort and date of ART initiation. If there was no viral load measurement collected 






initiation, if available. Records of pre-ART viral loads <1,000 copies/mL, which suggested 
unrecorded prior exposure to treatment, were excluded. 
 Year of ART initiation, which was based on the date of concurrent prescription of at least 
three antiretroviral drugs. This date was considered an indicator of starting a combination 
ART regimen. 
 ART regimen, which was coded as non-nucleoside reverse transcriptase inhibitor-based, 
protease inhibitor-based, integrase strand transfer inhibitor-based, or other.  
 CD4+ count, which serves as a measure of immune function and was expressed as T-
lymphocytes per microliter of blood (cells/mm3). 
 Clinical AIDS diagnosis, which was an indicator of having been diagnosed with an AIDS-
defining illness, according to the 1993 revised classification system for HIV infection and 
expanded surveillance case definition for AIDS.[38] 
 Chronic hepatitis B, which was based on positive/detectable laboratory test results for 
hepatitis B surface antigen, DNA, and/or envelope antigen. 
 Chronic hepatitis C, which was based on positive/detectable laboratory test results for 
hepatitis C antibody, RNA, and/or genotype. 
 Past cancer diagnosis (Aim 1 only), which was an indicator of ever having been diagnosed 
with any cancer, excluding nonmelanoma skin cancer. 
 Statin use, which was an indicator of ever having used a statin. 
 CNICS site, which was coded as one of the following: Case Western Reserve University; 
Fenway Community Health Center, Harvard University; Johns Hopkins University; 
University of Alabama at Birmingham; University of California, San Diego; University of 








Sex, race/ethnicity, sexual identity, and injection drug use were assessed at entry into the 
CNICS cohort. Pre-ART viral load, ART regimen, and year of ART initiation were assessed at 
ART initiation. Age, CD4 count, clinical AIDS status, status of other clinical conditions (chronic 
hepatitis B, chronic hepatitis C, past diagnosis of any cancer excluding nonmelanoma skin 
cancer), statin use, smoking status, at-risk alcohol use, and CNICS site were assessed at study 
baseline (six months after ART initiation). Restricted quadratic splines were used to model age 
and CD4 count, with knots at the 5th, 35th, 65th, and 95th percentiles.[39] All other covariates were 
modeled as indicator variables. 
 
3.D. Statistical analysis 
We used SAS version 9.4 (SAS Institute Inc., Cary, NC) for analyses, and R version 3.3.1 
(R Foundation for Statistical Computing, Vienna, Austria) for figures. 
 
3.D.1. Aim 1 
Imputing left-censored exposure data. Nearly 70% of viral load observations 
included in our analyses were reported to be below specified limits of detection. Simple 
substitution methods (e.g., replacement with the detection limit, half of the detection limit, the 
detection limit divided by the square root of two, or zero) are typically used to account for left-
censored exposure data but can result in substantial bias, particularly when the proportion of 
censoring is high. Assuming that viral load measurements were left censored at random 
conditional on observed covariates, an alternate approach is to fit a model with covariates 
associated with viral load and estimate model parameters by maximum likelihood[40, 41], which 
produces consistent estimates even when the proportion of left-censoring exceeds 50%.[41] 







For this study, we used a nonparametric multiple imputation approach with a left-
censoring score model to account for missing data. For each viral load observation, we used 
logistic regression to estimate the conditional probability of left censoring given all observed 
covariates and the outcome of interest, death from any cause.[43] We stratified the study cohort 
into five groups based on quintiles of the predicted probability of being left censored. 
Next, we computed nonparametric maximum likelihood estimates of the distribution 
function of viral load using the Turnbull estimator[44, 45] (equivalent to calculating reverse 
Kaplan-Meier estimates), stratified by quintiles of the left-censoring score. For each left-
censored viral load observation, a random number was generated from a uniform distribution 
on the interval (0, 1). Within each quintile of the left-censoring score, each random number was 
matched to the probability distribution function of viral load, and the corresponding viral load 
was assigned as the imputed viral load value for that left-censored observation. Each imputed 
viral load value was bounded between zero and the detection limit of the assay that produced the 
left-censored observation; if an imputed value ended up being above the detection limit, then 
another random number was generated until the corresponding viral load fell below the 
detection limit.  
We imputed all viral load observations that were too low to be quantified using assays 
with detection limits of 20, 30, 40, 48, 50, 75, or 400 copies/mL. We note that, with the CNICS 
data, we were not able to distinguish between left-censored viral loads and viral loads observed 
at detection limits. One hundred imputed datasets were generated for analysis.  
 
Time-to-event analysis. The start of follow-up for each patient was six months after 
the date of ART initiation. Patients were followed until death, and data were administratively 






year all-cause mortality from six months post-ART initiation were estimated using the following 
Cox proportional hazards model[46]: 
 
𝜆𝑘(𝑡) = 𝜆𝑘,0(𝑡) exp(𝛼𝑘𝑥𝑘,1 + 𝛽𝑘𝑥𝑘,2 + 𝛾𝑥3) 
 
where 𝑥𝑘,1 is 1 if viral load is between 20 and <𝑘 and 0 otherwise, 𝑥𝑘,2 is 1 if viral load is between 
𝑘 and 999 copies/mL and 0 otherwise, and 𝑥3 is 1 if viral load is above 999 copies/mL and 0 
otherwise. The reference category was viral load <20 copies/mL. We estimated hazard ratios for 
each of the viral load categories, for values of 𝑘 between 30 and 500 copies/mL. Efron’s 
approximation was used to handle tied event times.[47] 
We generated combined point estimates of hazard ratios for 10-year all-cause mortality 
by averaging across the 100 log hazard ratio estimates from the imputed datasets. We calculated 
robust standard errors for standardized hazard ratios, and used Rubin’s variance estimator[48] to 
combine variance within and between imputations. These overall hazard ratio and variance 
estimates were used to construct 95% Wald confidence intervals. The proportional hazards 
assumption was evaluated by examining plots of the log cumulative hazard by time and testing 
the product term of viral load and time; no notable violations of this assumption were identified.  
Additionally, we computed crude and standardized mortality risk over time using the 
Nelson-Aalen cumulative hazard function[49, 50], and constructed risk curves[51] averaged across 
all imputations and stratified by viral load category.  
 
Inverse probability of exposure weights. We used time-fixed inverse probability 
of exposure weights[52, 53] to control for differences at baseline among patients across the four 
viral load categories (<20, 20 to <𝑘, 𝑘 to 999, and >999 copies/mL) and standardize estimates 






estimated the conditional probability of being in each viral load category given all observed 
covariates. To improve efficiency, the weights were stabilized by the marginal probability of 
being in each viral load category for each 𝑘. The stabilized weights had a mean of 1.0 across all 
values of 𝑘 for all imputations, with an overall minimum of 0.13 and overall maximum of 15. 
For the analysis, we assumed no unmeasured or uncontrolled confounding, no selection 
bias, no interference, consistency, positive probability of every level of exposure for all strata of 
covariates, and correct specification of the weight and outcome models. 
 
Alternate analysis. For comparison purposes, we replaced left-censored observations 
with half of the detection limit, and calculated crude and standardized hazard ratios for 10-year 
all-cause mortality. In this alternative analysis, the weights used to standardize hazard ratio 
estimates to the total study population had a mean of 0.96 (range: 0.16, 19) across all 𝑘, after 
truncating at the 99.97 percentile.[52] We also generated crude and standardized risk curves for 
all-cause mortality over time. 
 
3.D.2. Aim 2 
 Combining multiple imputation and bootstrap estimation. Multiple 
imputation is a well-known approach to account for missing data, while the nonparametric 
bootstrap is often used to estimate standard errors in the absence of a closed-form solution for 
the standard error of an estimator. However, there is no standard approach to combine both 
methods. Studies that have combined multiple imputation and bootstrap estimation have 
generally taken one of two approaches: 1) multiply imputing the original data and then applying 
the bootstrap to each imputed dataset; or 2) applying the bootstrap to the original data, and 
then multiply imputing each bootstrap sample. Bootstrap methods are intended to mimic the 






as the population. This seems to point towards using the observed study sample with its original 
missing data structure intact (i.e., not imputed) when applying the bootstrap. Additionally, there 
may be efficiency benefits to first bootstrapping the original data and then imputing the 
bootstrap samples.[54] For this analysis, we chose to take this approach. 
First, we drew 200 nonparametric bootstrap samples with replacement from the original 
study sample. Then, using the nonparametric multiple imputation approach we employed for 
Aim 1, we imputed all left-censored viral load observations in the original study sample and each 
of the 200 bootstrap samples. For each viral load observation, we used logistic regression to 
estimate the conditional probability of left censoring given all observed covariates, first cancer 
diagnosis, and the competing risk of death. Thirty imputed datasets were generated for the 
original sample and each bootstrap sample. 
To estimate standard errors, we averaged across the point estimates calculated for the 30 
imputations for each bootstrap sample, and then computed the standard error of the 200 
averaged point estimates. These bootstrap standard error estimates were then used to construct 
confidence intervals for the combined point estimates calculated from the 30 imputations of the 
original study sample. Because we first applied the bootstrap to the original data and then 
multiply imputed the bootstrap samples, it was not necessary to calculate within- and between-
imputation variance as an intermediate step. 
 
Time-to-event analysis with competing risks. Studies that characterize cancer 
risk in HIV patients often measure incidence rates, typically expressed as the number of cancer 
events per 100,000 person-years, which assume that incident cancers occur at a constant rate 
over time. Here we estimated the probability of developing cancer over a specific 10-year period, 
which may provide a more intuitive measure of cumulative cancer risk. Additionally, the 






deaths in their analyses. Failing to use a competing risks approach and treating deaths as 
censored observations (i.e., using the Kaplan-Meier survival function or standard Cox 
proportional hazards estimates) ignores the fact that HIV patients may die before being 
diagnosed with cancer, and will thereby overestimate cancer risk. While censoring competing 
events may not lead to significant bias when the risk of the competing event is rare, death is not 
a rare event among HIV patients on treatment. Moreover, censoring competing events may lead 
to additional bias when the risk of the competing event is differential by exposure, as was the 
case in this study. 
The start of follow-up for each patient was six months after the date of ART initiation. 
Patients were followed until the earliest of the following: first cancer diagnosis, death, or loss to 
follow-up (defined as no recorded clinic visit or hospitalization for 18 months). Death from any 
cause without a cancer diagnosis was considered a competing event. Data were administratively 
censored after 10 years or on 31 December 2014. We used a proportional subdistribution 
hazards model[55] to compute nonparametric estimates of the cumulative incidence function of 
being diagnosed with incident cancer in the presence of the competing risk of death. A minimal 
amount of random jitter (up to one day) was added to tied event times. We calculated 10-year 
risk differences and risk ratios and constructed risk curves stratified by viral load category.[51]  
To calculate point estimates for cumulative incidence, risk differences, and risk ratios, 
we averaged across the point estimates calculated from the 30 imputations of the original study 
sample. We constructed 95% Wald confidence intervals using bootstrap standard error 
estimates, as described above. 
 
Inverse probability of exposure and censoring weights. We used time-fixed 
inverse probability of exposure weights[52, 53] to control for differences at baseline among 






and calculate estimates standardized to the total study population. Using a multinomial logistic 
regression model, we estimated the conditional probability of being in each viral load category 
given all observed covariates. To improve efficiency, the exposure weights were stabilized by the 
marginal probability of being in each viral load category. 
Additionally, because we did not have complete outcome ascertainment for Aim 2, we 
used time-varying inverse probability of censoring weights to account for potentially informative 
loss to follow-up by viral load category. The distribution of time to loss to follow-up was divided 
into five intervals. A logistic regression model was used to estimate the conditional probability 
of remaining in the study cohort during each time interval, given the viral load category and 
observed covariates. The censoring weights were stabilized by the probability of remaining in 
the study cohort, conditional on viral load category. The product of the stabilized exposure and 
censoring weights had a mean of 1.0 (range: 0.12, 13) in the imputed datasets of the original 
study sample.   
For the analysis, we assumed no unmeasured or uncontrolled confounding, no selection 
bias, no interference, consistency, positive probability of every level of exposure for all strata of 








CHAPTER 4. INCOMPLETE VIRAL SUPPRESSION AND MORTALITY IN HIV 
PATIENTS ON ANTIRETROVIRAL THERAPY 
 
4.A. Introduction 
The goal of antiretroviral therapy (ART) is to restore and maintain the health of people 
infected with human immunodeficiency virus (HIV) through suppression of HIV replication. In 
clinical practice, a concentration of HIV ribonucleic acid (RNA) below the detection limits of 
available assays is considered evidence of viral suppression. Despite advances in ART[56], not all 
HIV patients on treatment are able to achieve and maintain suppressed viral loads.[57]  
Low, detectable HIV RNA under 1,000 copies/mL has been studied as a potential risk 
factor for drug resistance, virologic failure, cancer, and mortality.[3-13, 26] However, the clinical 
significance of detectable viral loads in this range remains unclear, despite studies suggesting 
that patients with HIV or acquired immune deficiency syndrome (AIDS) who have low, 
detectable viral loads are at higher risk of experiencing adverse health outcomes compared to 
patients with undetectable viral loads.[3-5, 7, 8, 10, 11, 13, 26] 
Uncertainty about the effects of low, detectable viral load is due in part to variability in 
its definition. Clinical and epidemiologic studies typically set the upper bound of low viral load 
between 200 and 1,000 copies/mL, while the lower bound tends to be fixed at the detection 
limit of the viral load assay used in the study.[3-13, 26, 28-30] Defining a range of low, detectable viral 
load is further complicated when viral load measurements are obtained from multiple assays 
with different limits of detection, and when a considerable proportion of those measurements 






As access to effective ART scales up and the sensitivity of viral load assays improves over 
time, the number of HIV patients with low, detectable levels of HIV RNA observed in clinical 
practice will grow. Therefore, it is important to understand the implications of low, detectable 
viral load. The objective of this study is to determine whether a clinically significant threshold of 
detectable viral load under 1,000 copies/mL can be defined based on the relationship between a 




4.B.1. Study population 
We used data from the Center for AIDS Research (CFAR) Network of Integrated Clinical 
Systems (CNICS), a multicenter clinical cohort that currently includes over 30,000 HIV patients 
in the United States. CNICS maintains a clinical data repository from electronic medical record 
systems to support HIV research.[34] The CNICS cohort includes patients aged 18 years and older 
who initiated primary care in or after 1995 at one of eight CFAR sites: Case Western Reserve 
University; Fenway Community Health Center of Harvard University; Johns Hopkins 
University; University of Alabama at Birmingham; University of California, San Diego; 
University of California, San Francisco; University of North Carolina at Chapel Hill; and 
University of Washington. CNICS is a dynamic cohort, with approximately 1,400 new patients 
enrolling and 10% of patients leaving care annually.[34] 
All participants provided written informed consent to be included in the CNICS cohort, 
or contributed data with a waiver of written informed consent where approved by local 
institutional review boards. Upon entry into CNICS, demographic and historical information, 
including prior diagnoses and antiretroviral treatment, was collected. After enrollment, patient 






test results, and conditions diagnosed by providers. CNICS participants were typically seen in 
clinical care every three to four months, though frequency of follow-up was patient specific. 
A total of 27,865 patients entered the CNICS cohort between 1 January 1998 and 31 
December 2013. Patients who initiated monotherapy or dual therapy prior to or with no history 
of starting combination ART (defined as three or more ART drugs prescribed concurrently) 
(n=3,499), initiated ART prior to entering CNICS (n=6,405), initiated ART after 31 December 
2013 (n=282), had no history of initiating ART (n=4,067), died within six months of starting 
ART (n=130), or did not have at least one viral load measurement six months (-30/+90 days) 
after ART initiation (n=3,431) were excluded from our study. Patients with missing 
race/ethnicity information (n=93), no recorded CD4 count six months (-30/+90 days) after ART 
initiation (n=322), no pre-ART viral load measurement recorded between 60 days prior to 
CNICS entry and ART initiation (n=284), or pre-ART viral load measurements that suggested 
unrecorded prior exposure to treatment (<1,000 copies/mL) (n=1,408) were also excluded. A 
total of 7,944 patients was included in the final study sample. 
 
4.B.2. Mortality ascertainment 
The outcome of interest was time to death from any cause. All CNICS sites regularly 
query the National Death Index and state death certificate records to confirm recorded dates of 
deaths and capture unrecorded deaths among CNICS patients no longer in care. We used all-
cause mortality as our endpoint because cause of death data were unavailable for approximately 
35% of deaths recorded in CNICS.  
Because vital records are maintained on all patients enrolled in CNICS, including those 
not currently retained in care, we included deaths among patients no longer being seen in a 






reporting delays, which can result in underestimated mortality, and to allow sufficient time for 
CNICS sites to verify vital records. 
 
4.B.3. Viral load assessment 
The exposure of interest was HIV RNA six months (-30/+90 days) after ART initiation. 
For patients who had more than one viral load during the 120-day window, we used the 
measurement that was collected closest to six months after the date of ART initiation. Viral load 
measurements were determined by quantitative amplification assays and expressed as the 
number of HIV copies per milliliter of blood plasma (copies/mL). Viral load assays used in this 
study varied over time and by CNICS site; the lower limits of detection for the most commonly 
used assays were 20, 30, 40, 48, 50, 75, and 400 copies/mL. Viral load measurements six 
months after ART initiation ranged from 6 to over 4 million copies/mL.  
 
4.B.4. Statistical analysis 
The majority of viral load observations included in our analyses were reported to be 
below specified limits of detection. We assumed that these viral load measurements were left 
censored at random conditional on observed covariates, and used a nonparametric multiple 
imputation approach with a left-censoring score model to account for missing data. For each 
viral load observation, we used logistic regression to estimate the conditional probability of left 
censoring given age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, 
smoking status, at-risk alcohol use, pre-ART viral load, year of ART initiation, ART regimen, 
CD4 count, clinical AIDS status, status of other clinical conditions (chronic hepatitis B, chronic 
hepatitis C, past diagnosis of any cancer excluding nonmelanoma skin cancer), statin use, study 






knots at the 5th, 35th, 65th, and 95th percentiles.[39] We stratified the study cohort into five groups 
based on quintiles of the predicted probability of being left censored. 
Next, we computed nonparametric maximum likelihood estimates of the distribution 
function of viral load using the Turnbull estimator[44, 45], stratified by quintiles of the left-
censoring score, and used these estimates to impute left-censored viral load observations. We 
imputed all viral load observations that were too low to be quantified using assays with detection 
limits of 20, 30, 40, 48, 50, 75, or 400 copies/mL, and imputed values were bounded between 
zero and the assay detection limit. One hundred imputed datasets were generated for analysis.  
The start of follow-up for each patient was six months after the date of ART initiation. 
Patients were followed until death, and data were administratively censored after 10 years or on 
31 December 2014. Hazard ratios for 10-year all-cause mortality from six months post-ART 
initiation were estimated using the following Cox proportional hazards model[46]: 
 
𝜆𝑘(𝑡) = 𝜆𝑘,0(𝑡) exp(𝛼𝑘𝑥𝑘,1 + 𝛽𝑘𝑥𝑘,2 + 𝛾𝑥3) 
 
where 𝑥𝑘,1 is 1 if viral load is between 20 and <𝑘 and 0 otherwise, 𝑥𝑘,2 is 1 if viral load is between 
𝑘 and 999 copies/mL and 0 otherwise, and 𝑥3 is 1 if viral load is above 999 copies/mL and 0 
otherwise. The reference category was viral load <20 copies/mL. We estimated hazard ratios for 
each of the viral load categories, for possible threshold values of 𝑘 between 30 and 500 
copies/mL. Efron’s approximation was used to handle tied event times.[47] 
We used inverse probability of exposure weights[52, 53] to control for differences at 
baseline among patients across the four viral load categories (<20, 20 to <𝑘, 𝑘 to 999, and >999 
copies/mL) and standardize estimates to the total study population. Sex, race/ethnicity, male-
to-male sexual contact, and injection drug use were assessed at entry into the CNICS cohort. 






Age, smoking status, at-risk alcohol use, CD4 count, clinical AIDS status, status of other clinical 
conditions (chronic hepatitis B, chronic hepatitis C, past diagnosis of any cancer excluding 
nonmelanoma skin cancer), statin use, and study site were assessed at study baseline. Restricted 
quadratic splines were used to model age and CD4 count. Using a multinomial logistic 
regression model for each 𝑘, we estimated the conditional probability of being in each viral load 
category, and calculated stabilized weights. The weights had a mean of 1.0 across all 𝑘 for all 
imputations, with an overall minimum of 0.13 and overall maximum of 15. 
We generated combined point estimates of hazard ratios for 10-year all-cause mortality 
by averaging across the 100 log hazard ratio estimates from the imputed datasets. We calculated 
robust standard errors for standardized hazard ratios, and used Rubin’s variance estimator[48] to 
combine variance within and between imputations. These overall hazard ratio and variance 
estimates were used to construct 95% Wald confidence intervals. The proportional hazards 
assumption was evaluated by examining plots of the log cumulative hazard by time and testing 
the product term of viral load and time; no notable violations of this assumption were identified. 
We computed mortality risk over time using the Nelson-Aalen cumulative hazard function[49, 50], 
and constructed risk curves[51] averaged across all imputations and stratified by viral load 
category.  
Additionally, for comparison, we replaced left-censored observations with half of the 
detection limit, and calculated hazard ratios for 10-year all-cause mortality and generated risk 
curves. In this alternate analysis, the weights used to standardize hazard ratio estimates to the 
total study population had a mean of 0.96 (range: 0.16, 19) across all 𝑘, after truncating at the 
99.97 percentile.[52] We used SAS version 9.4 (SAS Institute Inc., Cary, NC) for analyses, and R 








We identified 7,944 CNICS patients (49,118 person-years) who met our study inclusion 
criteria (Table 4.1). Of the patients included in the study, the median age at baseline (six months 
after ART initiation) was 40 (interquartile range [IQR]: 32, 46) years, 83% were male, 45% were 
white/Caucasian, 37% were black/African American, 62% identified as men who have sex with 
men, and 12% reported having ever injected drugs. The median pre-ART viral load was 74,827 
(IQR: 22,394, 237,780) copies/mL, median year of ART initiation was 2007 (IQR: 2003, 2010), 
and median CD4 count was 349 (IQR: 193, 532) cells/mm3. At baseline, 29% of study patients 
had been diagnosed with AIDS, 47% were prescribed a non-nucleoside reverse transcriptase 
inhibitor-based regimen, and 40% had been prescribed a protease inhibitor-based regimen. 
Patients were followed for a median of 6.2 (IQR: 3.5, 10) years, and 862 deaths from any cause 
were recorded during the study period.  
Of the patients included in this study, 68% had viral loads six months after ART 
initiation that were left censored at assay detection limits (Appendix 4.1).  After imputation, an 
average of 57% of all viral load measurements (84% of left-censored observations) fell below 20 
copies/mL. Fifteen percent of study patients had viral loads of at least 1,000 copies/mL six 
months after ART initiation. Plots of the distribution of viral load comparing nonparametric 
multiple imputation to simple substitution (replacing left-censored observations with half of the 
detection limit) are shown in Figure 4.1. 
Standardized hazard ratio estimates at specific values of 𝑘 are shown in Table 4.2 (see 
Appendix 4.2a for crude hazard ratio estimates). Viral load measurements were categorized as 
<20 copies/mL (reference group), 20 to <𝑘 copies/mL, 𝑘 to 999 copies/mL, and >999 
copies/mL. In aggregate, viral load measurements of 20 to 999 copies/mL were not associated 
with increased 10-year all-cause mortality, when compared to viral loads under 20 copies/mL 






comparing 𝑘 to 999 copies/mL to <20 copies/mL, we observed an increase in the standardized 
10-year hazard ratio for mortality at values of 𝑘 discernable at 130 copies/mL (standardized HR: 
1.39, 95% CI: 1.02, 1.88). As expected, viral loads >999 copies/mL were strongly associated with 
increased mortality (standardized HR: 1.96, 95% CI: 1.56, 2.46). Plots of standardized hazard 
ratio estimates and 95% confidence intervals by 𝑘 indicated there was no demonstrable viral 
load threshold between 30 and 500 copies/mL associated with a marked increase in 10-year 
mortality (Figure 4.2; see Appendix 4.2b for plots of crude hazard ratios).  
Standardized risk curves for all-cause mortality at specific values of 𝑘 are shown in 
Figure 4.3 (see Appendix 4.2c for crude risk curves). Again, we observed an increase in the 
standardized risk of 10-year mortality with increasing viral load at baseline. The average 
standardized risk of 10-year mortality was approximately 14% among patients with viral loads 
between 20 and 400 copies, which was similar to the risk among patients with viral loads <20 
copies/mL (13%). There was a 20% standardized risk of death among patients with viral loads 
between 400 and 999 copies/mL, comparable to the risk among patients with viral loads >999 
copies/mL (23%). 
Hazard ratio estimates for 10-year all-cause mortality and risk curves, generated after 
replacing left-censored viral load observations with half of the detection limit, are shown in 
Appendix 4.3a–e. With this simple substitution approach, the majority (58%) of viral load 
observations were between 20 and 50 copies/mL, while a comparatively low proportion (8%) of 
viral loads fell below 20 copies/mL. Patterns in hazard ratio estimates were similar to what we 
observed with estimates calculated using multiply-imputed viral loads, though the magnitude of 
hazard ratio estimates was higher across all values of 𝑘 using the substitution method of 
handling left-censored viral load observations. We also observed similar trends in the risk 






mortality over time among patients with viral loads <20 copies/mL based on data generated 
from simple substitution. 
 
4.D. Discussion 
The objective of this study was to determine whether there was a threshold of HIV viral 
load under 1,000 copies/mL early after the start of therapy associated with increased mortality, 
while systematically accounting for undetectable viral load results. We did not identify a clear 
low-level viral load threshold between 30 and 500 copies/mL that corresponded with a marked 
increase in 10-year all-cause mortality. Rather, we observed a gradual increase in standardized 
hazard ratio estimates with increasing viral load, discernable at 130 copies/mL. The average 
standardized 10-year mortality risk among patients with viral loads between 400 and 999 
copies/mL at baseline approached the standardized risk of mortality among patients with viral 
loads between 1,000 and 4 million copies/mL (20% vs. 23%). 
The US Department of Health and Human Services and the AIDS Clinical Trials Group 
currently define virologic failure as one confirmed viral load measurement over 200 
copies/mL.[35] Here, using a single measurement after six months of therapy, we observed a 44% 
increase in the hazard of death among patients with viral loads between 200 and 999, compared 
to those with viral loads under 20 copies/mL (standardized HR: 1.44, 95% CI: 1.00, 2.07). The 
average standardized 10-year mortality risk among patients with low-level viral loads between 
200 and 999 copies/mL at baseline was 17%, which was higher than the average standardized 
risk of mortality among patients with viral loads under 20 copies/mL (14%).  
In this study, exposure status was based on one viral load measurement collected 
approximately six months after ART initiation. Because a single detectable viral load 
measurement could represent either a transient increase in viral load or sustained low-level HIV 






varying measures of viral load to assess exposure is warranted for future analysis. That said, we 
observed a clear pattern of increasing 10-year mortality risk with increasing viral load, based on 
one viral load measurement under 1,000 copies/mL after six months of therapy. We also 
observed that a single viral load measurement at or above 1,000 copies/mL six months after 
ART initiation was strongly associated with 10-year mortality. This suggests that a single viral 
load measurement collected six months after initiating ART remains highly informative 
regarding the risk of death over 10 years. 
By using data from CNICS, the largest clinical cohort of HIV patients in the US, we 
expect our study findings to be generalizable to treated adult HIV patients engaged in clinical 
care at academic medical centers in the US. Because patients who died within six months of 
initiating ART were excluded from the study population, we expect that the results of this study 
are applicable to patients who start treatment early enough in the disease course to be effective. 
There may be unmeasured confounding that impacts our findings, and we note that a viral load 
measurement collected shortly after starting therapy may be a proxy for unmeasured variables, 
such as socioeconomic status. We assumed that variables included in the analyses were 
measured without error, which is unlikely for self-reported behaviors such as tobacco, alcohol, 
and illicit drug use; however, we do not expect measurement error of confounders to be 
differential by exposure or outcome.  
We did not account for adherence, switching, or cessation of ART regimen in the 
analyses. For each treatment-naïve patient, we considered the first recorded date of concurrent 
prescription of three or more ART drugs as an indicator of starting a combination ART regimen, 
and ignored changes in treatment. Approximately 85% of patients included in our study had 
viral loads under 1,000 copies/mL six months after ART initiation, and we assumed that 
patients not taking their medication as prescribed were likely assigned to the highest viral load 






relatively small number of events among patients with viral loads between 500 and 999 
copies/mL six months after starting therapy. We also note that, because we had limited follow-
up for patients whose viral loads were assessed with ultrasensitive assays, it would be prudent to 
reevaluate our estimates after additional person-time has accumulated in the CNICS cohort. 
Nearly 70% of viral load observations included in our analyses were left censored. Simple 
substitution methods (e.g., replacement with a constant value such as the assay detection limit, 
half the detection limit, the detection limit divided by the square root of two, or zero) are often 
used to account for left-censored exposure data but can result in substantial bias, particularly 
when the proportion of censoring is high.[41, 58] Another approach is to impute left-censored 
exposure data by maximum likelihood[41, 59], but this is problematic when the data do not closely 
follow a known parametric distribution.[42] Here, we used nonparametric multiple imputation to 
account for left-censored viral loads. This allowed us to effectively compare undetectable viral 
load observations collected over time using assays with different detection limits, without having 
to rely on distributional assumptions. As shown in Figure 4.1, simple substitution resulted in the 
majority of viral loads being amassed at specific values determined by assay detection limits, 
while multiple imputation produced a more biologically plausible depiction of the underlying 
distribution of viral load.  
Using simple substitution resulted in far fewer left-censored viral loads that were 
categorized as under 20 copies/mL (8% vs. 57% with multiple imputation). Standardized hazard 
ratio estimates indicated an increased hazard of death for patients at all low-level viral loads 
between 20 and 999 copies/mL at baseline, due to a markedly lower risk of death among 
patients with viral loads under 20 copies/mL compared to patients in the same viral load 
category based on multiply-imputed data (4% vs. 13%). Almost 60% of patients with viral loads 
under 20 copies/mL based on data generated by simple substitution received care from the 






viral load category based on multiply-imputed data represented all study sites and started ART 
during all years included in the study period. Using simple substitution resulted in violations of 
positivity, and fitting the weight model to data generated after simple substitution yielded 
extreme values, which we did not observe when fitting the same weight model to data generated 
from multiple imputation. Due to these factors, the hazard ratio and risk estimates we calculated 
using our nonparametric multiple imputation approach were attenuated but likely less biased 
than estimates calculated using simple substitution data. 
Detectable viral loads under 1,000 copies/mL may indicate ongoing low-level HIV 
replication due to inadequate response to treatment, drug resistance, drug interactions, or 
incomplete adherence to therapy or care. Occurrences of low, detectable viral load, whatever the 
underlying cause, will be more commonly observed in HIV patients as access to antiretroviral 
therapy increases and assay sensitivity improves over time. While we observed an increased 
hazard of death with low-level viral loads, discernable at 130 copies/mL, this association was 
largely driven by the elevated mortality risk experienced by patients with viral loads between 
400 and 999 copies/mL. Patients with viral loads in this higher range, which suggested partial 
response to treatment, faced a similar long-term risk of mortality as patients with high viral 
loads that indicated overt treatment failure. Low-level viral loads between 400 and 999 
copies/mL shortly after starting ART appear to place patients at a significantly higher 10-year 
risk of death than patients with viral loads under 20 copies/mL, and occurrences of viral loads 
in this range may need to be treated similarly as viral loads that exceed 1,000 copies/mL. Given 
the importance of rapidly achieving virologic suppression after initiating treatment, further 











4.E. Tables and figures 
Table 4.1. Demographic, clinical, and behavioral characteristics of 7,944 CNICS patients six months after ART initiation, between 1 




 Total  
n=7,944 
 <20 cpm  
n=4,545 
 20–999 cpm  
n=2,184 
 >999 cpm 
n=1,215 
 No. (%)  No. (%)  No. (%)  No. (%) 
         
Age, yearsa   40 (32, 46)  40 (32, 47)  40 (33, 47)  39 (32, 45) 
Maleb  6,566 (82.7)  3,790 (83.4)  1,833 (83.9)  943 (77.6) 
Race/ethnicityb         
   White, non-Hispanic   3,581 (45.1)  2,163 (47.6)  971 (44.5)  447 (36.8) 
   Black, non-Hispanic   2,908 (36.6)  1,482 (32.6)  835 (38.2)  591 (48.6) 
   Other, non-Hispanic  401 (5.1)  254 (5.6)  101 (4.6)  46 (3.8) 
   Hispanic  1,054 (13.3)  646 (14.2)  277 (12.7)  131 (10.8) 
MSM, everb  4,917 (61.9)  2,946 (64.8)  1,331 (60.9)  640 (52.7) 
IDU, everb  979 (12.3)  477 (10.5)  277 (12.7)  225 (18.5) 
Smoking, ever  2,605 (32.8)  1,451 (31.9)  708 (32.4)  466 (36.7) 
At-risk alcohol use, ever  1,197 (15.1)  654 (14.4)  317 (14.5)  226 (18.6) 
Pre-ART viral load, cpma,c  74,827 (22,394; 237,780)  56,048 (17,593; 170,000)  111,880 (36,295; 372,848)  93,928 (30,900; 294,966)  
Year of ART initiationa,c  2007 (2003, 2010)  2008 (2004, 2010)  2006 (2002, 2009)  2004 (2001, 2008) 
ART regimenc         
   NNRTI-based  3,747 (47.2)  2,463 (54.2)  852 (39.0)  432 (35.6) 
   PI-based  3,188 (40.1)  1,519 (33.4)  1,048 (48.0)  621 (51.1) 
   INSTI-based  431 (5.4)  313 (6.9)  87 (4.0)  31 (2.6) 
   Other  578 (7.3)  229 (5.5)  198 (9.1)  131 (10.8) 
CD4 count, cells/mm3 a  349 (193, 532)  405 (245, 574)  321 (184, 496)  191 (71, 355) 
Clinical AIDS diagnosis  2,313 (29.1)  1,101 (24.2)  740 (33.9)  472 (38.9) 
Chronic hepatitis B  209 (2.6)  91 (2.0)  66 (3.0)  52 (4.3) 
Chronic hepatitis C  650 (8.2)  327 (7.2)  177 (8.1)  146 (12.0) 
Past cancer diagnosis  429 (5.4)  240 (5.3)  121 (5.5)  68 (5.6) 
Statin use, ever  250 (3.2)  167 (3.7)  59 (2.7)  24 (2.0) 
         
 
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; INSTI, integrase inhibitor; IQR, 
interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor 
a Median (interquartile range). 
b Assessed at entry into CNICS cohort. 






Figure 4.1. Distribution of viral loads up to 200 copies/mL for 7,944 CNICS patients six 
months after ART initiation. Dotted line indicates 20 copies/mL. A. After nonparametric 
multiple imputation of left-censored viral load observations, averaged over 100 
imputations; B. After substitution of left-censored viral load observations with half of 











Table 4.2. Standardized hazard ratio estimates for 10-year all-cause mortality for 7,944 CNICS patients, by selected viral load 
threshold values of 𝑘, combined from 100 imputations. 
 














20 to <𝒌  
cpm 




𝒌 to 999  
cpm 










20  310 4545 1  — — —  230 2184 1.18 (0.93, 1.50)  1215 1.96 (1.56, 2.46)d 
30      54 535 1.17 (0.75, 1.84)  176 1649 1.17 (0.91, 1.50)    
40      75 708 1.19 (0.81, 1.73)  155 1476 1.18 (0.91, 1.52)    
50      96 934 1.17 (0.83, 1.66)  134 1215 1.18 (0.92, 1.53)    
75      121 1273 1.10 (0.79, 1.47)  109 911 1.29 (0.98, 1.70)    
100      142 1454 1.12 (0.85, 1.50)  88 730 1.25 (0.93, 1.68)    
130      152 1592 1.09 (0.83, 1.44)  78 592 1.39 (1.02, 1.88)    
200      174 1776 1.11 (0.85, 1.44)  56 409 1.44 (1.00, 2.07)    
300      189 1912 1.11 (0.86, 1.43)  41 272 1.58 (1.07, 2.35)    
400      197 1991 1.12 (0.87, 1.45)  33 193 1.74 (1.10, 2.74)    
500      201 2041 1.11 (0.86, 1.43)  29 143 1.77 (1.05, 2.99)    
                
 
Abbreviation: cpm, copies/mL. 
a Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, smoking, at-risk 
alcohol use, pre-ART viral load, year of ART initiation, ART regimen, CD4 count, clinical AIDS status, status of other clinical 
conditions (chronic hepatitis B, chronic hepatitis C, past diagnosis of any cancer excluding nonmelanoma skin cancer), statin use, and 
study site.  
b Averaged over 100 imputations, rounded to nearest integer. 
c Viral load <20 copies/mL was reference category across 𝑘. 






Figure 4.2. Standardized hazard ratios and 95% confidence intervals for 10-year all-cause 
mortality for 7,944 CNICS patients, by viral load threshold 𝑘, for viral loads between 𝑘 and 999 
copies/mL, combined from 100 imputations. Standardized estimates controlled for age, sex, 
race/ethnicity, male-to-male sexual contact, injection drug use, smoking, at-risk alcohol use, 
pre-ART viral load, year of ART initiation, ART regimen, CD4 count, clinical AIDS status, status 
of other clinical conditions (chronic hepatitis B, chronic hepatitis C, past diagnosis of any cancer 
excluding nonmelanoma skin cancer), statin use, and study site. Upper dashed line indicates 
hazard ratio for 10-year all-cause mortality for viral loads >999 copies/mL; lower dashed line 













Figure 4.3. Standardized risk curves for all-cause mortality for 7,944 CNICS patients, for selected viral load threshold values of 𝑘, 
stratified by viral load category, averaged over 100 imputations. Standardized estimates controlled for age, sex, race/ethnicity, male-
to-male sexual contact, injection drug use, smoking, at-risk alcohol use, pre-ART viral load, year of ART initiation, ART regimen, CD4 
count, clinical AIDS status, status of other clinical conditions (chronic hepatitis B, chronic hepatitis C, past diagnosis of any cancer 
excluding nonmelanoma skin cancer), statin use, and study site. Solid line represents viral loads <20 copies/mL, dot-dashed line 
represents viral loads between 20 and 𝑘 copies/mL, dashed line represents viral loads between 𝑘 and 999 copies/mL, dotted line 








CHAPTER 5. CANCER RISK IN HIV PATIENTS WITH INCOMPLETE VIRAL 
SUPPRESSION AFTER INITIATION OF ANTIRETROVIRAL THERAPY 
 
5.A. Introduction 
Effective antiretroviral therapy (ART) typically suppresses human immunodeficiency 
virus (HIV) levels to below the detection limits of assays used in clinical practice in the United 
States. Treatment with ART has resulted in lower incidence of acquired immune deficiency 
syndrome (AIDS)-defining illnesses, prolonged survival, and rising incidence of non-AIDS-
defining cancers and chronic diseases among people living with HIV.[1] Cancer is the second-
leading cause of death in the US[60] and a significant cause of morbidity and mortality in HIV 
patients.[1, 2] The risk of developing particular cancers may be higher among people infected with 
HIV compared to the general population due to immunosuppression, oncogenic viral 
coinfections, and elevated prevalence of certain risk behaviors, such as smoking and alcohol 
abuse.[20, 21]   
Not all HIV patients on treatment are able to achieve and maintain undetectable viral 
loads, and the impact of low levels of detectable HIV ribonucleic acid (RNA) on the risk of 
comorbid disease, such as cancer, remains unclear. Prior studies suggest that low-level HIV 
RNA on ART increases the risk of certain cancers[61, 62]; however, the association between early 
virologic control and cancer risk has not been evaluated. Optimally, patients initiating ART 
would achieve undetectable HIV RNA within six months[35], and here we explore whether failure 
to achieve this milestone is associated with cancer risk. Because low HIV RNA may be associated 
with ongoing inflammation[6, 27], it is biologically plausible that low, detectable viral load has 
predictive value in assessing the long-term risk of developing various cancers, particularly those 





after initiation of ART may also be a marker of suboptimal adherence that could influence long-
term clinical outcomes. The objective of this study is to examine 10-year cancer risk among HIV 
patients on ART based on a single low-level viral load measurement collected six months after 




5.B.1. Study population 
We used data from the Center for AIDS Research (CFAR) Network of Integrated Clinical 
Systems (CNICS), a multicenter clinical cohort of over 30,000 HIV patients in the United States. 
CNICS maintains a clinical data repository from electronic medical record systems to support 
HIV research.[34] The CNICS cohort includes patients aged 18 years and older who initiated 
primary care in or after January 1995 at one of eight CFAR sites: Case Western Reserve 
University; Fenway Community Health Center of Harvard University; Johns Hopkins 
University; University of Alabama at Birmingham; University of California, San Diego; 
University of California, San Francisco; University of North Carolina at Chapel Hill; and 
University of Washington. CNICS is a dynamic cohort, with approximately 1,400 new patients 
enrolling and 10% of patients leaving care annually.[34] 
All participants provided written informed consent to be included in the CNICS cohort, 
or contributed data with a waiver of written informed consent where approved by local 
institutional review boards. Upon entry into CNICS, demographic and historical information, 
including prior diagnoses and antiretroviral treatment, was collected. After enrollment, patient 
data were prospectively captured at clinic visits and include prescribed medications, laboratory 
test results, and conditions diagnosed by providers. CNICS participants were typically seen in 





A total of 27,865 patients entered the CNICS cohort between 1 January 1998 and 31 
December 2013. Patients who initiated monotherapy or dual therapy prior to or with no history 
of starting combination ART (defined as three or more ART drugs prescribed concurrently) 
(n=3,499), initiated ART prior to entering CNICS (n=6,405), initiated ART after 31 December 
2013 (n=282), had no history of initiating ART (n=4,067), were diagnosed with cancer prior to 
ART initiation (n=570), were diagnosed with cancer within six months of starting ART (n=151), 
died within six months of starting ART (n=99), or did not have at least one viral load 
measurement six months (-30/+90 days) after ART initiation (n=3,285) were excluded from our 
study. Patients with missing race/ethnicity information (n=88), no recorded CD4 count six 
months (-30/+90 days) after ART initiation (n=308), no pre-ART viral load measurement 
collected between 60 days prior to CNICS entry and ART initiation (n=261), or pre-ART viral 
load measurements that suggested unrecorded prior exposure to treatment (<1,000 copies/mL) 
(n=1,335) were excluded. The final study sample comprised 7,515 patients. 
 
5.B.2. Viral load assessment 
The exposure of interest was HIV RNA six months after ART initiation. For patients who 
had more than one eligible viral load measurement during the 120-day window, we used the 
measurement that was closest to six months after the date of ART initiation. Viral loads 
measurements were determined by quantitative amplification assays and expressed as the 
number of HIV copies per milliliter of blood plasma (copies/mL). Viral load assays used in this 
study varied over time and by CNICS site; the lower limits of detection for the most commonly 
used assays were 20, 30, 40, 48, 50, 75, and 400 copies/mL. Observed viral load measurements 







5.B.3. Endpoint ascertainment 
The outcome of interest was time to diagnosis of first invasive cancer, excluding 
nonmelanoma skin cancer. All cancer cases diagnosed through 31 December 2014 and recorded 
at the CNICS sites were verified by medical record review.[64] Cancer data collected by CNICS 
included date of diagnosis, tumor site, diagnosis method (histopathology, clinical exam, 
radiography, or historical information), histology, stage, and grade.  
Death from any cause was considered a competing risk in the analysis. National Death 
Index and state death certificate records were queried regularly by all CNICS sites to confirm all 
recorded dates of deaths. 
  
5.B.4. Statistical analysis 
The start of follow-up for each patient was six months after the date of ART initiation. 
Patients were followed until the earliest of the following: first cancer diagnosis, death, or loss to 
follow-up (defined as no recorded clinic visit or hospitalization for 18 months). Death from any 
cause without a cancer diagnosis was considered a competing event. Data were administratively 
censored after 10 years or on 31 December 2014. 
 We used a proportional subdistribution hazards model[55] to compute nonparametric 
estimates of the cumulative incidence function of being diagnosed with incident cancer in the 
presence of the competing risk of death, and calculated 10-year risk differences and risk ratios 
and constructed risk curves stratified by viral load category.[51] We drew 200 nonparametric 
bootstrap samples with replacement from the original study population to estimate standard 
errors.  
The majority of viral load observations included in our analyses were reported to be 
below specified lower limits of detection (i.e., 20, 30, 40, 48, 50, 75, and 400 copies/mL). For 
the original study population and each bootstrap sample, we used a nonparametric imputation 





viral load observation, we used logistic regression to estimate the conditional probability of left 
censoring given age, sex, race/ethnicity, sexual identity, injection drug use, CD4 count, clinical 
AIDS status, year of ART initiation, ART regimen, pre-ART viral load, chronic hepatitis status, 
statin use, smoking status, at-risk alcohol use, CNICS site, death, and incident cancer.[43] 
Restricted quadratic splines were used to model age and CD4 count, with knots at the 5th, 35th, 
65th, and 95th percentiles.[39] We computed nonparametric maximum likelihood estimates[44, 45] 
of the distribution function of viral load, stratified by quintiles of the predicted probability of 
being left censored, and used these estimates to impute left-censored viral load observations. 
Thirty imputed datasets were generated for the original study population and each bootstrap 
sample. 
 Patients were assigned to the following exposure categories based on their observed or 
imputed viral load at baseline (six months after ART initiation): <20 copies/mL, 20 to 199 
copies/mL, 200 to 999 copies/mL, and >999 copies/mL. Because the US Department of Health 
and Human Services and the AIDS Clinical Trials Group currently define virologic failure as one 
confirmed viral load measurement at or above 200 copies/mL[35], we divided low-level viral 
loads into two categories, 20 to 199 copies/mL, and 200 to 999 copies/mL. The reference 
category was viral load <20 copies/mL. 
We used inverse probability of exposure weights[52, 53] to control for differences at 
baseline among patients across the four viral load categories and calculate estimates 
standardized to the total study population. Sex, race/ethnicity, sexual identity, and injection 
drug use were assessed at entry into the CNICS cohort. Pre-ART viral load, ART regimen, and 
year of ART initiation were assessed at ART initiation. Age, CD4 count, clinical AIDS status, 
chronic hepatitis status, statin use, smoking status, at-risk alcohol use, and CNICS site were 
assessed at study baseline. Restricted quadratic splines were used to model age and CD4 count. 
Using a multinomial logistic regression model, we estimated the conditional probability of 





Additionally, we estimated inverse probability of censoring weights to account for 
potentially informative loss to follow-up by viral load category. Both weights were stabilized, 
and the product of the stabilized weights had a mean of 1.0 in the imputed datasets of the 
original study sample, with a minimum of 0.12 and maximum of 13. We used SAS version 9.4 
(SAS Institute Inc., Cary, NC) for analyses, and R version 3.3.1 (R Foundation for Statistical 
Computing, Vienna, Austria) for figures. 
 
5.C. Results 
We identified 7,515 CNICS patients (40,110 person-years) who met our study inclusion 
criteria (Table 5.1). Of the patients included in the study, the median age at baseline (six months 
after ART initiation) was 39 (interquartile range [IQR]: 32, 46) years, 82% were male, 45% were 
white/Caucasian, 37% were black/African American, 61% identified as men who have sex with 
men, and 13% reported having ever injected drugs. The median pre-ART viral load was 66,691 
(IQR: 19,820, 219,732) copies/mL, median year of ART initiation was 2007 (IQR: 2003, 2010), 
and median CD4 count was 363 (IQR: 207, 541) cells/mm3. At baseline, 26% of study patients 
had been diagnosed with AIDS, 41% had been prescribed a protease inhibitor (PI)-based 
regimen, and 47% were prescribed a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based regimen. Patients were followed for a median of 4.9 (IQR: 2.7, 8.1) years; 14% of the study 
cohort were followed for 10 years. A total of 290 cancer diagnoses and 560 deaths from any 
cause without a cancer diagnosis were recorded during the study period, and 1,731 (23%) 
patients were lost to follow up. 
 Of the 7,515 patients included in the study, 68% had viral loads six months after ART 
initiation that were left censored at assay detection limits. After imputation, 56% of all viral 
loads were under 20 copies/mL, 23% were between 20 and 199 copies/mL, 5% were between 
200 and 999 copies/mL, and 15% were over 999 copies/mL. Patients differed across viral load 





initiation were more likely to be white/Caucasian, identify as men who have sex with men, have 
higher CD4 counts, have lower pre-ART viral loads, have started ART in the latter half of the 
study period, have been prescribed an NNRTI-based regimen, and have been prescribed statins. 
Patients with viral loads <20 copies/mL six months after starting ART were less likely to report 
injection drug use, have been prescribed a PI-based regimen, have chronic hepatitis, report 
having ever smoked, or report at-risk alcohol use. 
The most common cancers observed in our study population were non-Hodgkin 
lymphoma (n=39 cases, or 13.4% of all cancer cases), Kaposi sarcoma (n=37; 12.8%), lung 
cancer (n=30, 10.3%), Hodgkin lymphoma (n=26; 9.0%), prostate cancer (n=22; 7.6%), anal 
cancer (n=18; 6.8%), breast cancer (n=14; 4.8%), and liver cancer (n=14; 4.8%) (Table 5.2). 
Crude and standardized 10-year cumulative incidence, risk difference, and risk ratio estimates 
for first cancer diagnosis are shown in Table 5.3. The crude cancer risk in the study sample was 
7.03% (95% confidence interval [CI]: 6.08%, 7.98%). The highest crude cancer risk was 
observed among patients with viral loads between 200 and 999 copies/mL six months after ART 
initiation (10.7%), with the risk of cancer diagnosis ranging from 6.60% to 7.67% in the other 
three viral load categories.  
After controlling for baseline characteristics, the overall 10-year cancer risk was 6.90% 
(95% CI: 5.69%, 8.12%), with little variation in cancer risk by viral load category (range: 6.76% 
to 7.44%). There was a marked reduction in the cumulative cancer incidence estimate for 
patients with viral loads between 200 and 999 copies/mL (crude risk of 10.7% vs. standardized 
risk of 6.82%); race/ethnicity, year of ART initiation, ART regimen, baseline CD4 count, and 
study site accounted for 75% of the change in estimate in this viral load category. Among 
patients with viral loads between 200 and 999 copies/mL six months after ART initiation who 
were diagnosed with cancer, 62% were black (compared to 47% of all cases in the total study 
population), 52% started ART between 1998 and 2000 (vs. 21%), 63% had been prescribed a PI-





starting therapy (vs. 36%). Crude and standardized risk curves for 10-year cumulative cancer 
incidence are shown in Figure 5.1. 
The overall standardized risk of death without a cancer diagnosis, which was considered 
a competing risk in the analysis, was 12.2% (95% CI: 10.2%, 14.2%) (Appendix 5.1–5.2). The risk 
of death differed by viral load category, ranging from 10.7% among patients with viral loads 
under 20 copies/mL to 18.1% among patients with viral loads of at least 1,000 copies/mL six 
months after starting ART.  
 
5.D. Discussion 
The objective of this study was to evaluate 10-year cancer risk among HIV patients on 
antiretroviral therapy with low viral load under 1,000 copies/mL, while accounting for death 
from any cause as a competing event. The crude 10-year risk of first cancer was highest for 
patients with viral loads between 200 and 999 copies/mL after six months of therapy, though 
there was no association between HIV RNA six months after ART initiation and risk of first 
cancer after controlling for confounders at baseline. 
 Nearly 70% of the viral load observations used in the analysis fell below assay detection 
limits, which was expected given that the study population had been on ART for six months at 
baseline. Prior studies have typically replaced left-censored viral load observations with a 
constant value, which can result in substantial bias, particularly when the proportion of 
censoring is high.[41, 58] In a previous study of total mortality in a similar sample of CNICS 
patients, using a simple substitution approach to account for left-censored viral loads resulted in 
violations of positivity, unstable weights, and upwardly biased hazard ratio estimates.[65] Here, 
we used nonparametric multiple imputation to account for left-censored viral loads. This 
approach allowed for the comparison of undetectable viral load observations collected over time 
using assays with different detection limits, without imposing assumptions about the underlying 





Studies that characterize cancer risk in HIV patients often measure incidence rates, 
typically expressed as the number of cancer events per 100,000 person-years, which assume 
that incident cancers occur at a constant rate over time. Here we estimated the probability of 
developing cancer over a specific 10-year period, which may provide a more intuitive measure of 
cumulative cancer risk. Additionally, the majority of previous studies evaluating cancer trends 
among people with HIV have censored deaths in their analyses. Failing to use a competing risks 
approach and treating deaths as censored observations (i.e., using the Kaplan-Meier survival 
function or standard Cox proportional hazards estimates) ignores the fact that HIV patients may 
die before being diagnosed with cancer, and will thereby overestimate cancer risk. While 
censoring competing events may not lead to significant bias when the risk of the competing 
event is rare, we observed nearly twice as many deaths as first cancer diagnoses in our study 
sample of HIV patients on treatment. Moreover, censoring competing events may lead to 
additional bias when the risk of the competing event is differential by exposure, as was the case 
in this study. We expect that we arrived at less biased risk estimates by modeling the cumulative 
incidence function of cancer, while accounting for death from any cause without a cancer 
diagnosis as a competing risk. 
Here, exposure status was based on a single HIV RNA measurement collected 
approximately six months after ART initiation, as we considered this a relevant marker of early 
treatment success. However, a single detectable viral load measurement could represent either a 
transient increase in viral load or sustained low-level HIV RNA concentrations in the detectable 
range, so using time-varying measures of viral load to assess exposure is warranted to better 
understand the dynamic nature of HIV RNA suppression. We did not account for adherence, 
switching, or cessation of ART regimen in the analyses. For each treatment-naïve patient, we 
considered the first recorded date of concurrent prescription of three or more ART drugs as an 
indicator of starting a combination ART regimen, and ignored changes in treatment. We 





for self-reported behaviors such as tobacco, alcohol, and illicit drug use; however, we do not 
expect measurement error of confounders to be differential by exposure or outcome. Outcome 
misclassification was minimized in this study as cancer cases were confirmed through medical 
record review, and deaths verified using national and state death records. We also assumed that 
our models were correctly specified, and that there were no unmeasured or unknown 
confounders that would significantly impact our findings. 
Nearly a quarter of our study sample was lost to follow-up over the study period, and 
patients were followed for a median of five years. Given that the outcome of interest was 10-year 
cancer risk, it may be necessary to reassess our risk estimates after additional person-time has 
accumulated in the CNICS cohort. The precision of our estimates was limited by the relatively 
small number of cancer cases observed in our study population, so pooling data from other 
clinical cohorts to verify our results is warranted. Nevertheless, we expect that the results of this 
study are generalizable to HIV patients receiving care and treatment at academic medical 
centers in the US, and we observed clinically meaningful trends that highlight potential avenues 
for cancer screening and prevention among people living with HIV. In this study, non-Hodgkin 
lymphoma, Kaposi sarcoma, lung cancer, Hodgkin lymphoma, prostate cancer, anal cancer, 
breast cancer, and liver cancer were the most commonly observed cancer types, consistent with 
prior studies of cancer in HIV patients after the introduction of ART.[1, 2, 66] This has implications 
for targeted cancer screening for HIV patients, as well as preventive interventions such as 
smoking cessation programs and human papillomavirus and hepatitis B vaccination. We also 
observed a higher proportion of Hodgkin lymphoma cases among patients with lower viral 
loads, possibly related to immune reconstitution.[67] 
We observed a 10-year standardized first cancer risk of 6.9% in our sample of HIV 
patients after starting therapy. After controlling for baseline characteristics, there was no 
association between the risk of any first cancer over ten years and early response to ART. This 





HIV patients after ART initiation. While we found that the risk of any first cancer was similar 
across viral load categories, it would be worth exploring possible differences in cancer types by 









5.E. Tables and figures 
Table 5.1. Demographic, clinical, and behavioral characteristics of 7,515 CNICS patients six months after ART initiation, averaged 




 Total  
n=7,515 
 <20 cpm  
n=4,281 
 20–199 cpm  
n=1,694 
 200–999 cpm  
n=393 
 >999 cpm 
n=1,147 
 No. (%)  No. (%)  No. (%)  No. (%)  No. (%) 
           
Age, years a  39 (32, 46)  39 (32, 47)  40 (33, 46)  40 (34, 47)  39 (32, 45) 
Male b  6,180 (82.2)  3,553 (83.0)  1,421 (82.5)  324 (80.7)  882 (76.9) 
Race/ethnicity b           
   White, non-Hispanic   3,343 (44.5)  2,008 (46.9)  759 (44.8)  160 (40.7)  416 (36.3) 
   Black, non-Hispanic   2,800 (37.3)  1,426 (33.3)  627 (37.0)  181 (46.0)  566 (49.3) 
   Other, non-Hispanic  375 (5.0)  238 (5.6)  78 (4.6)  16 (4.2)  43 (3.7) 
   Hispanic  997 (13.3)  609 (14.2)  230 (13.6)  36 (9.1)  122 (10.6) 
MSM, ever b  4,611 (61.4)  2,753 (64.3)  1,037 (61.2)  224 (56.9)  597 (52.0) 
IDU, ever b  938 (12.5)  451 (10.5)  205 (12.1)  67 (17.1)  215 (18.7) 
Smoking, ever  2,474 (32.9)  1,366 (31.9)  555 (32.8)  129 (32.8)  424 (37.0) 
At-risk alcohol use, ever  1,125 (15.0)  609 (14.2)  244 (14.4)  58 (14.6)  214 (18.7) 
Pre-ART viral load, cpm a,c  73,320 (22,000; 234,048)  55,133 (17,296; 166,966)  109,225 (35,253; 349,189)  103,356 (35,573; 427,215)  93,071 (30,122; 299,230)  
Year of ART initiation a,c  2007 (2003, 2010)  2008 (2004, 2010)  2006 (2002, 2009)  2006 (2002, 2009)  2005 (2001, 2008) 
ART regimen c           
   NNRTI-based  3,570 (47.5)  2,335 (54.5)  691 (40.8)  136 (34.6)  409 (35.7) 
   PI-based  2,997 (39.9)  1,420 (33.2)  782 (46.2)  209 (53.2)  586 (51.1) 
   INSTI-based  405 (5.4)  290 (6.8)  75 (4.4)  10 (2.5)  30 (2.6) 
   Other  543 (7.2)  236 (5.5)  147 (8.7)  38 (9.6)  122 (10.6) 
CD4 count, cells/mm3 a  356 (201, 537)  412 (254, 581)  338 (197, 511)  299 (177, 456)  204 (75, 362) 
Clinical AIDS diagnosis  1,985 (26.4)  918 (21.4)  521 (30.7)  130 (33.1)  417 (36.4) 
Chronic hepatitis B  193 (2.6)  82 (1.9)  50 (3.0)  11 (2.9)  49 (4.3) 
Chronic hepatitis C  612 (8.1)  307 (7.2)  135 (8.0)  34 (8.8)  135 (11.8) 
Statin use, ever  236 (3.1)  158 (3.7)  45 (2.6)  11 (2.8)  22 (1.9) 
           
 
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; cpm, copies per milliliter; INSTI, integrase 
inhibitor; IDU, injection drug use; IQR, interquartile range; MSM, men who have sex with men; NNRTI, non-nucleoside reverse 
transcriptase inhibitor; PI, protease inhibitor 
a Median (interquartile range). 
b Assessed at entry into CNICS cohort. 





Table 5.2. Number (%) of cancers observed in 7,515 CNICS patients, averaged over 30 
imputations (rounded to nearest integer). 
 
   
Total 
n=7,515 
 <20  
cpm 
n=4,281 
 20–199  
cpm 
n=1,694 
 200–999  
cpm 
n=393 
 >999  
cpm 
n=1,147 
           
All cancers  290 (100)  152 (100)  62 (100)  22 (100)  54 (100) 
Non-Hodgkin lymphoma  39 (13.4)  17 (11.2)  11 (17.7)  2 (9.1)  9 (16.7) 
Kaposi sarcoma  37 (12.8)  17 (11.2)  5 (8.1)  3 (13.6)  12 (22.2) 
Lung cancer  30 (10.3)  18 (11.8)  6 (9.7)  1 (4.5)  5 (9.3) 
Hodgkin lymphoma  26 (9.0)  18 (11.8)  5 (8.1)  1 (4.5)  2 (3.7) 
Prostate cancer  22 (7.6)  12 (7.9)  8 (12.9)  1 (4.5)  1 (1.9) 
Anal cancer  18 (6.8)  8 (5.3)  5 (8.1)  3 (13.6)  4 (7.4) 
Breast cancer  14 (4.8)  10 (6.6)  3 (4.8)  0  1 (1.9) 
Liver cancer  14 (4.8)  7 (4.6)  2 (3.2)  1 (4.5)  4 (7.4) 
Skin cancer (melanoma)  11 (3.8)  4 (2.6)  3 (4.8)  1 (4.5)  3 (5.6) 
Oral cavity and pharyngeal cancer  10 (3.4)  5 (3.3)  1 (1.6)  1 (4.5)  3 (5.6) 
Kidney cancer  8 (2.8)  4 (2.6)  1 (1.6)  2 (9.1)  1 (1.9) 
Colon cancer  6 (2.3)  4 (2.6)  2 (3.2)  0  0 
Leukemia  6 (2.3)  3 (2.0)  1 (1.6)  0  2 (3.7) 
Laryngeal cancer  5 (1.7)  3 (2.0)  2 (3.2)  0  0 
Multiple myeloma  5 (1.7)  2 (1.3)  2 (3.2)  0  2 (3.7) 
Cervical cancer  4 (1.4)  2 (1.3)  1 (1.6)  0  1 (1.9) 
Esophageal cancer  3 (1.0)  2 (1.3)  1 (1.6)  0  0 
Thyroid cancer  3 (1.0)  2 (1.3)  0  1 (4.5)  0 
Uterine cancer  3 (1.0)  2 (1.3)  1 (1.6)  0  0 
Brain and nervous system cancer  2 (0.7)  2 (1.3)  0  0  0 
Testicular cancer  2 (0.7)  2 (1.3)  0  0  0 
Rectal and rectosigmoid cancer  2 (0.7)  1 (0.7)  1 (1.6)  0  0 
Peritoneal & retroperitoneal cancer  2 (0.7)  1 (0.7)  0  0  1 (1.9) 
Bladder cancer  1 (0.3)  1 (0.7)  0  0  0 
Ovarian cancer  1 (0.3)  1 (0.7)  0  0  0 
Soft tissue cancer  1 (0.3)  1 (0.7)  0  0  0 
Stomach cancer  1 (0.3)  1 (0.7)  0  0  0 
Vaginal cancer  1 (0.3)  0  1 (1.6)  0  0 
Vulvar cancer  1 (0.3)  0  0  1 (4.5)  0 
Pancreatic cancer  1 (0.3)  0  0  0  1 (1.9) 
Small intestine cancer  1 (0.3)  0  0  0  1 (1.9) 
Other (unspecified site)  8 (2.8)  3 (2.0)  1 (1.6)  3 (13.6)  1 (1.9) 
           
 









Table 5.3. Crude and standardized 10-year cumulative incidence, risk difference, and risk ratio estimates for first cancer diagnosis in 
7,515 CNICS patients, averaged over 30 imputations.  
  
     Crude  Standardized a 






 Risk, %  
(95% CI) 




 Risk, %  
(95% CI) 




            
Total 290 7,515 40,110  7.03 (6.08, 7.98)    6.90 (5.69, 8.12)   
<20 cpm 152 4,281 22,392  6.60 (5.34, 7.86) 0 1  6.76 (5.12, 8.39) 0 1 
20 to 199 cpm 62 1,694 9,625  6.71 (5.25, 8.17) 0.10 (-1.74, 1.94) 1.02 (0.73, 1.30)  6.88 (5.08, 8.68) 0.12 (-2.08, 2.33) 1.02 (0.68, 1.36) 
200 to 999 cpm 22 393 2,124  10.7 (5.74, 15.6) 4.08 (-0.92, 9.08) 1.62 (0.83, 2.40)  6.82 (3.50, 10.1) 0.06 (-3.73, 3.86) 1.01 (0.43, 1.59) 
>999 cpm 54 1,147 5,969  7.67 (5.31, 10.0) 1.07 (-1.69, 3.84) 1.16 (0.72, 1.61)  7.44 (4.10, 10.8) 0.68 (-3.05, 4.41)  1.10 (0.53, 1.67) 
            
 
Abbreviations: CI, confidence interval; cpm, copies per milliliter; RD, risk difference; RR, risk ratio 
a Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, smoking, at-risk 
alcohol use, pre-ART viral load, year of ART initiation, ART regimen, CD4 count, clinical AIDS status, chronic hepatitis status), statin 






Figure 5.1. Crude and standardized risk curves for first cancer diagnosis in 7,515 CNICS 
patients, stratified by viral load category, averaged over 100 imputations. Standardized 
estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, 
smoking, at-risk alcohol use, pre-ART viral load, year of ART initiation, ART regimen, CD4 
count, clinical AIDS status, chronic hepatitis status, statin use, and study site. Solid line 
represents viral loads <20 copies/mL, dot-dashed line represents viral loads between 20 and 
199 copies/mL, dashed line represents viral loads between 200 and 999 copies/mL, dotted line 







CHAPTER 6. CONCLUSIONS 
 
6.A. Summary of findings 
 The objective of Aim 1 of this project was to determine whether there was a threshold of 
HIV RNA under 1,000 copies/mL early after treatment initiation associated with increased 10-
year all-cause mortality. We did not identify a clear low-level viral load threshold between 30 
and 500 copies/mL that corresponded with a marked increase in 10-year all-cause mortality. 
Rather, we observed a gradual increase in standardized hazard ratio estimates with increasing 
viral load, discernable at 130 copies/mL. The standardized 10-year mortality risk among 
patients with viral loads between 400 and 999 copies/mL at baseline approached the 
standardized risk of mortality among patients with viral loads between 1,000 and 4 million 
copies/mL (20% vs. 23%). 
Patients with viral loads between 400 and 999 copies/mL, which suggested partial 
response to treatment, faced a similar long-term risk of mortality as patients with viral loads 
between 1,000 and 4 million copies/mL, which indicated overt treatment failure. Low-level viral 
loads between 400 and 999 copies/mL shortly after starting ART appear to place patients at a 
significantly higher 10-year risk of death than patients with viral loads under 20 copies/mL, and 
occurrences of viral loads in this range may need to be treated similarly as viral loads that 
exceed 1,000 copies/mL. 
The objective of Aim 2 was to evaluate the impact of detectable viral load under 1,000 
copies/mL on risk of first cancer. In our study sample, we observed a standardized risk of first 
cancer diagnosis of 6.90% (95% CI: 5.69%, 8.12%). We did not identify an association between 





the relationship between HIV RNA and first cancer risk is time dependent and cannot be 
adequately captured by a single viral load measurement. The most commonly observed cancers 
in our overall study population were non-Hodgkin lymphoma, Kaposi sarcoma, lung cancer, 
Hodgkin lymphoma, prostate cancer, anal cancer, breast cancer, and liver cancer. This provides 
support for targeted cancer screening for HIV patients, as well as preventive interventions such 
as smoking cessation programs and human papillomavirus and hepatitis B vaccination. 
Nearly 70% of viral load observations included in our analyses were left censored, a 
significant yet often ignored analytic issue that arises when studying HIV patients on 
antiretroviral therapy. Here, we used a nonparametric multiple imputation approach to account 
for left-censored viral loads. Prior studies have typically replaced left-censored viral load 
observations with a constant value, which can result in substantial bias, particularly when the 
proportion of censoring is high.[41, 58] Our nonparametric multiple imputation approach allowed 
us to effectively compare undetectable viral load observations collected over time using assays 
with different detection limits, without having to rely on distributional assumptions. In our 
alternate analysis for Aim 1, we showed that simple substitution (replacement with half of assay 
detection limits) resulted in the majority of viral loads being amassed at specific values 
determined by assay detection limits, while multiple imputation produced a more biologically 
plausible depiction of the underlying distribution of viral load. Additionally, using a simple 
substitution approach to account for left-censored viral loads resulted in violations of positivity, 
unstable weights, and upwardly biased estimates of association. By using our nonparametric 
multiple imputation approach, our estimates were attenuated but likely less biased than 
estimates calculated using simple substitution data. 
For Aim 2, we calculated estimates of the cumulative incidence of first cancer diagnosis 
while accounting for death as a competing event. Studies that characterize cancer risk in HIV 
patients often measure incidence rates, typically expressed as the number of cancer events per 





Here we estimated the probability of developing cancer over a specific 10-year period, which 
may provide a more intuitive measure of cumulative cancer risk. Additionally, the majority of 
previous studies evaluating cancer trends among people with HIV have censored deaths in their 
analyses. Failing to use a competing risks approach and treating deaths as censored 
observations ignores the fact that HIV patients may die before being diagnosed with cancer, and 
will thereby overestimate cancer risk. While censoring competing events may not lead to 
significant bias when the risk of the competing event is rare, we observed nearly twice as many 
deaths as first cancer diagnoses in our study sample of HIV patients on treatment. Moreover, 
censoring competing events may lead to additional bias when the risk of the competing event is 
differential by exposure, as was the case in this study. We expect that we arrived at less biased 
risk estimates by modeling the cumulative incidence function of cancer, while accounting for 
death from any cause without a cancer diagnosis as a competing risk. 
Here, exposure status was based on one viral load measurement collected approximately 
six months after ART initiation. Because a single detectable viral load measurement could 
represent either a transient increase in viral load or sustained low-level HIV RNA 
concentrations in the detectable range, which are likely disparate risk factors, using time-
varying measures of viral load to assess exposure is warranted for future analysis. That said, we 
observed a clear pattern of increasing 10-year mortality risk with increasing viral load, based on 
one viral load measurement under 1,000 copies/mL after six months of therapy. We also 
observed that a single viral load measurement at or above 1,000 copies/mL six months after 
ART initiation was strongly associated with 10-year mortality. This suggests that a single viral 
load measurement collected six months after initiating ART remains highly informative 
regarding the risk of death over 10 years. However, a single viral load measurement may be less 
useful for other long-term outcomes, such as cancer diagnosis.  
Because patients who died within six months of initiating ART were excluded from the 





treatment early enough in the disease course to be effective. We assumed that variables included 
in the analyses were measured without error, which is unlikely for self-reported behaviors such 
as drug and alcohol use. However, we expect that outcome misclassification was minimized 
because deaths were verified using national and state death records, and cancer cases were 
verified by medical record review. We also assumed that our models were correctly specified, 
and that there were no unmeasured or unknown confounders that would significantly impact 
our findings.  
We did not account for adherence, switching, or cessation of ART regimen in the 
analyses. For each treatment-naïve patient, we considered the first recorded date of concurrent 
prescription of three or more ART drugs as an indicator of starting a combination ART regimen, 
and ignored changes in treatment. Approximately 85% of patients included in our study had 
viral loads under 1,000 copies six months after ART initiation, and we assumed that patients not 
taking their medication as prescribed were likely assigned to the highest viral load category 
(>999 copies/mL).  
The precision of our estimates was limited by the relatively small number of events 
observed in our study population, so pooling data from other clinical cohorts to verify our 
results is warranted. For Aim 1, we did not evaluate values of 𝑘 above 500 copies/mL due to the 
small number of events among patients with viral loads between 500 and 999 copies/mL six 
months after starting therapy. That said, we expect that the results of this study are likely 
generalizable to HIV patients receiving care and treatment at academic medical centers in the 
US. We note that the CNICS cohort is disproportionately male and non-Hispanic white, 
compared to the overall population of HIV-infected adults in the US. 
 
6.B. Future directions 
Using time-varying viral load measurements to assess exposure would better 





therapy on long-term outcomes, such as mortality and cancer risk. Given the high proportion of 
left-censored viral loads we observed in this study, and the biased estimates that result from 
using simple substitution to account for these left-censored viral loads, investigating methods to 
efficiently impute left-censored viral load measurements at multiple time points is warranted. 
Viral loads that fall below the detection limits of modern viral load assays generally 
indicate successful treatment, while high viral loads at or above 1,000 copies/mL after starting 
therapy likely result from not taking antiretroviral medications as prescribed. Occurrences of 
detectable viral loads under 1,000 copies/mL may be due to a number of factors, both biological 
and behavioral. These include inadequate physiologic response to treatment, drug resistance, 
drug interactions, or incomplete adherence to therapy or care. Given the fact that viral loads in 
this range will be more commonly observed as access to antiretroviral therapy increases and 
assay sensitivity improves over time, this study may motivate further research on treatment 
adherence among CNICS patients, or laboratory research using CNICS biospecimens to 
investigate inflammatory markers and other factors that may explain partial treatment 
response.  
Furthermore, while it is becoming increasingly evident that the HIV epidemic in the US 
is shifting to older adults, far less attention and fewer resources have been allocated to 
examining this trend in the developing world. As access to ART continues to scale up globally, 
we can expect to observe a similar demographic shift among people living with HIV in 
developing countries, along with similar increases in the incidence of comorbid chronic 
conditions. This shift supports further exploration of the prevalence of detectable HIV RNA 
under 1,000 copies/mL and its potential impact on mortality, cancer, and other chronic diseases 






6.C. Public health impact 
This study highlights the importance of rapid HIV RNA suppression after therapy 
initiation. Our findings indicate that HIV patients with incomplete viral suppression shortly 
after starting antiretroviral therapy may require closer clinical monitoring and intervention, 
such as intensification or change of therapy, in order to increase the prospect of successful 








APPENDIX 4.1. Number (%) of 7,944 CNICS patients with viral load measurements observed or left censored at lower limits of 
detection for assays most commonly used during study period, by year of start of follow up. 
 






20 30 40 48 50 75 400 
          
Total 7,944  212 (3.1) 299 (4.4) 1,095 
(16.0) 
365 (5.3) 1,626 
(23.7) 
820 (12.0) 238 (3.5) 
1998 85  0 0 0 0 32 (37.7) 0 15 (17.7) 
1999 268  1 (0.4) 0 1 (0.4) 0 117 (43.7) 0 44 (16.4) 
2000 376  0 0 1 (0.3) 0 174 (46.3) 3 (0.8) 39 (10.4) 
2001 445  1 (0.2) 0 0 0 191 (42.9) 5 (1.1) 47 (10.6) 
2002 384  0 1 (0.3) 1 (0.3) 1 (0.3) 168 (43.8) 26 (6.8) 21 (5.5) 
2003 438  0 23 (5.3) 1 (0.2) 0 129 (29.5) 95 (21.7) 21 (4.8) 
2004 493  0 47 (9.5) 1 (0.2) 0 146 (29.6) 87 (17.7) 13 (2.6) 
2005 451  0 46 (10.2) 2 (0.4) 0 122 (27.1) 112 (24.8) 16 (3.6) 
2006 521  0 51 (9.8) 0 0 186 (35.7) 99 (19.0) 15 (2.9) 
2007 547  0 50 (9.1) 14 (2.6) 3 (0.6) 199 (36.4) 113 (20.7) 14 (2.6) 
2008 624  0 64 (10.3) 66 (10.6) 72 (11.5) 157 (25.2) 94 (15.1) 7 (1.1) 
2009 720  0 37 (5.1) 187 (26.0) 146 (20.3) 77 (10.7) 70 (9.7) 4 (0.6) 
2010 662  0 0 275 (41.5) 121 (18.3) 48 (7.3) 48 (7.3) 5 (0.8) 
2011 665  61 (9.2) 0 288 (43.3) 66 (9.2) 34 (5.1) 50 (7.5) 0 
2012 577  123 (21.3) 2 (0.4) 213 (36.9) 26 (4.5) 8 (1.4) 47 (8.2) 1 (0.2) 
2013 495  91 (18.4) 0 200 (40.4) 16 (3.2) 6 (1.2) 37 (7.5) 0 
2014 193  41 (21.2) 0 63 (32.6) 14 (7.3) 0 19 (9.8) 0 









APPENDIX 4.2A. Crude hazard ratio estimates for 10-year all-cause mortality for 7,944 CNICS patients, by selected viral load 
threshold values of 𝑘, combined from 100 imputations. 
 














20 to <𝒌  
cpm 




𝒌 to 999  
Cpm 






               
322 
  
20  310 4545 1  — — —  230 2184 1.43 (1.15, 1.78)  1251 3.75 (3.18, 4.43)c 
30      54 535 1.37 (0.89, 2.11)  176 1649 1.45 (1.17, 1.80)    
40      75 708 1.44 (1.00, 2.06)  155 1476 1.43 (1.14, 1.78)    
50      96 934 1.41 (1.01, 1.95)  134 1215 1.45 (1.16, 1.80)    
75      121 1273 1.30 (0.97, 1.73)  109 911 1.61 (1.28, 2.04)    
100      142 1454 1.32 (1.01, 1.73)  88 730 1.64 (1.28, 2.11)    
130      152 1592 1.30 (1.00, 1.68)  78 592 1.80 (1.39, 2.33)    
200      174 1776 1.32 (1.04, 1.69)  56 409 1.90 (1.42, 2.55)    
300      189 1912 1.34 (1.06, 1.70)  41 272 2.06 (1.47, 2.88)    
400      197 1991 1.34 (1.07, 1.69)  33 193 2.33 (1.62, 3.35)    
500      201 2041 1.34 (1.06, 1.68)  29 143 2.77 (1.88, 4.07)    
                
 
Abbreviation: cpm, copies/mL. 
a Averaged over 100 imputations, rounded to nearest integer. 
b Viral load <20 copies/mL was reference category across 𝑘. 






APPENDIX 4.2B. Crude hazard ratios and 95% confidence intervals for 10-year all-cause 
mortality for 7,944 CNICS patients, by viral load threshold 𝑘, for viral loads between 𝑘 and 999 




Upper dashed line indicates hazard ratio for 10-year all-cause mortality for viral loads >999 










APPENDIX 4.2C. Crude risk curves for all-cause mortality for 7,944 CNICS patients, for selected viral load threshold values of 𝑘, 




Solid line represents viral loads <20 copies/mL, dot-dashed line represents viral loads between 20 and 𝑘 copies/mL, dashed line 
represents viral loads between 𝑘 and 999 copies/mL, dotted line represents viral loads >999 copies/mL. A. 𝑘 = 20 copies/mL; B. 𝑘 = 








APPENDIX 4.3A. Crude hazard ratio estimates for 10-year all-cause mortality for 7,944 CNICS patients, by selected viral load 
threshold values of 𝑘, with left-censored viral load observations substituted with half of assay detection limit. 
 














20 to <𝒌  
cpm 




𝒌 to 999  
cpm 






               
322 
  
20  39 674 1  — — —  501 6055 1.19 (0.86, 1.65)  1251 3.83 (2.75, 5.34) 
30      276 3623 1.15 (0.82, 1.61)  225 2432 1.24 (0.88, 1.74)   3.83 (2.75, 5.34) 
40      336 4552 1.08 (0.78, 1.51)  165 1503 1.48 (1.05, 2.10)   3.83 (2.75, 5.35) 
50      339 4640 1.08 (0.77, 1.50)  162 1415 1.52 (1.07, 2.15)   3.83 (2.75, 5.35) 
75      356 4919 1.07 (0.77, 1.48)  145 1136 1.66 (1.16, 2.36)   3.84 (2.75, 5.35) 
100      375 5091 1.08 (0.78, 1.50)  126 964 1.69 (1.18, 2.42)   3.83 (2.75, 5.35) 
130      384 5221 1.08 (0.78, 1.50)  117 834 1.79 (1.25, 2.58)   3.84 (2.75, 5.35) 
200      404 5395 1.09 (0.79, 1.52)  97 660 1.84 (1.27, 2.67)   3.84 (2.75, 5.35) 
300      461 5787 1.14 (0.83, 1.59)  40 268 2.10 (1.35, 3.27)   3.83 (2.75, 5.34) 
400      468 5862 1.15 (0.83, 1.59)  33 193 2.37 (1.49, 3.78)   3.83 (2.75, 5.34) 
500      472 5912 1.15 (0.83, 1.59)  29 143 2.83 (1.75, 4.57)   3.83 (2.75, 5.34) 
                
 
Abbreviation: cpm, copies/mL. 









APPENDIX 4.3B. Standardized hazard ratio estimates for 10-year all-cause mortality for 7,944 CNICS patients, by selected viral 
load threshold values of 𝑘, with left-censored viral load observations substituted with half of assay detection limit. 
 














20 to <𝒌  
cpm 




𝒌 to 999  
cpm 






               
322 
  
20  39 674 1  — — —  501 6055 1.84 (1.19, 2.82)  1251 3.34 (2.13, 5.24) 
30      276 3623 1.72 (1.07, 2.76)  225 2432 2.09 (1.30, 3.35)   3.51 (2.17, 5.66) 
40      336 4552 1.80 (1.16, 2.78)  165 1503 2.00 (1.27, 3.15)   3.39 (2.16, 5.32) 
50      339 4640 1.81 (1.17, 2.79)  162 1415 2.01 (1.27, 3.18)   3.40 (2.17, 5.32) 
75      356 4919 1.76 (1.14, 2.72)  145 1136 2.17 (1.36, 3.46)   3.40 (2.17, 5.34) 
100      375 5091 1.80 (1.17, 2.78)  126 964 2.08 (1.30, 3.33)   3.41 (2.18, 5.35) 
130      384 5221 1.78 (1.15, 2.74)  117 834 2.22 (1.38, 3.58)   3.41 (2.17, 5.34) 
200      404 5395 1.86 (1.18, 2.92)  97 660 2.44 (1.45, 4.10)   3.54 (2.22, 5.66) 
300      461 5787 1.76 (1.15, 2.71)  40 268 2.68 (1.54, 4.65)   3.35 (2.14, 5.25) 
400      468 5862 1.79 (1.16, 2.75)  33 193 2.63 (1.46, 4.74)   3.35 (2.14, 5.26) 
500      472 5912 1.77 (1.15, 2.73)  29 143 2.63 (1.41, 4.90)   3.35 (2.14, 5.25) 
                
 
Abbreviation: cpm, copies/mL. 
a Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, smoking, at-risk 
alcohol use, pre-ART viral load, year of ART initiation, ART regimen, CD4 count, clinical AIDS status, status of other clinical 
conditions (chronic hepatitis B, chronic hepatitis C, past diagnosis of any cancer excluding nonmelanoma skin cancer), statin use, and 
study site. 





APPENDIX 4.3C. Crude and standardized hazard ratios and 95% confidence intervals for 10-
year all-cause mortality for 7,944 CNICS patients, by viral load threshold 𝑘, for viral loads 
between 𝑘 and 999 copies/ml, with left-censored viral load observations substituted with half of 




Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, 
injection drug use, smoking, at-risk alcohol use, pre-ART viral load, year of ART initiation, ART 
regimen, CD4 count, clinical AIDS status, status of other clinical conditions (chronic hepatitis B, 
chronic hepatitis C, past diagnosis of any cancer excluding nonmelanoma skin cancer), statin 
use, and study site. Upper dashed line indicates hazard ratio for 10-year all-cause mortality for 









APPENDIX 4.3D. Crude risk curves for all-cause mortality for 7,944 CNICS patients, for selected viral load threshold values of 𝑘, 





Solid line represents viral loads <20 copies/mL, dot-dashed line represents viral loads between 20 and 𝑘 copies/mL, dashed line 
represents viral loads between 𝑘 and 999 copies/mL, dotted line represents viral loads >999 copies/mL. A. 𝑘 = 20 copies/mL; B. 𝑘 = 








APPENDIX 4.3E. Standardized risk curves for all-cause mortality for 7,944 CNICS patients, for selected viral load threshold values 
of 𝑘, stratified by viral load category, with left-censored viral load observations substituted with half of assay detection limit. 
  
 
Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, smoking, at-risk alcohol use, pre-
ART viral load, year of ART initiation, ART regimen, CD4 count, clinical AIDS status, status of other clinical conditions (chronic hepatitis B, 
chronic hepatitis C, past diagnosis of any cancer excluding nonmelanoma skin cancer), statin use, and study site. Solid line represents viral loads 
<20 copies/mL, dot-dashed line represents viral loads between 20 and 𝑘 copies/mL, dashed line represents viral loads between 𝑘 and 999 








APPENDIX 5.1. Crude and standardized 10-year cumulative incidence, risk difference, and risk ratio estimates for death without a 
cancer diagnosis in 7,515 CNICS patients, averaged over 30 imputations. 
 
     Crude  Standardized a 






 Risk, %  
(95% CI) 




 Risk, %  
(95% CI) 




            
Total 560 7,515 40,110  12.7 (11.5, 13.9)    12.2 (10.2, 14.2)   
<20 cpm 196 4,281 22,392  8.99 (7.60, 10.4) 0 1  10.7 (8.18, 13.2) 0 1 
20 to 199 cpm 112 1,694 9,625  11.5 (9.55, 13.5) 2.55 (0.34, 4.75) 1.28 (1.01, 1.55)  11.5 (9.11, 13.8) 0.74 (-1.68, 3.17) 1.07 (0.83, 1.30) 
200 to 999 cpm 37 393 2,124  14.7 (9.55, 19.9) 5.73 (0.29, 11.2) 1.64 (0.99, 2.28)  15.0 (8.86, 21.1) 4.25 (-2.53, 11.0) 1.40 (0.73, 2.06) 
>999 cpm 215 1,147 5,969  26.3 (22.9, 29.7) 17.3 (13.6, 21.0) 2.93 (2.31, 3.55)  18.1 (13.7, 22.5) 7.38 (2.40, 12.4) 1.69 (1.14, 2.24) 
            
 
Abbreviations: CI, confidence interval; cpm, copies per milliliter; RD, risk difference; RR, risk ratio 
a Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, injection drug use, smoking, at-risk 
alcohol use, pre-ART viral load, year of ART initiation, ART regimen, CD4 count, clinical AIDS status, chronic hepatitis status, statin 






APPENDIX 5.2. Crude and standardized risk curves for death without a cancer diagnosis in 
7,515 CNICS patients, stratified by viral load category, averaged over 100 imputations. 
 
 
Standardized estimates controlled for age, sex, race/ethnicity, male-to-male sexual contact, 
injection drug use, smoking, at-risk alcohol use, pre-ART viral load, year of ART initiation, ART 
regimen, CD4 count, clinical AIDS status, chronic hepatitis status, statin use, and study site. 
Solid line represents viral loads <20 copies/mL, dot-dashed line represents viral loads between 
20 and 199 copies/mL, dashed line represents viral loads between 200 and 999 copies/mL, 
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